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Chapter 1 
INTRODUCTION 
10 
The pathogenesis of hepatic encephalopathy is still not known. Ammonia was one of 
the first compounds considered as a cause of encephalopathy. Therapy, therefore, was 
aimed at decreasing pathological plasma ammonia concentrations in patients with 
hepatic encephalopathy. This approach, however, was often insufficient and new 
theories on the pathogenesis with implications for treatment were developed. The 
imbalance between aromatic and branched chain amino acids was thought to promote 
the accumulation of false neurotransmitters which in turn could lead to hepatic 
encephalopathy. However, the effect of therapy with branched chain amino acids was 
disappointing and the GABA-benzodiazepine theory was proposed. Reports on the 
beneficial effect of the benzodiazepine antagonist flumazenil on hepatic encephalopathy 
seemed to indicate a new therapeutic strategy. 
CLINICAL ASPECTS 
Before the pathogenesis and treatment of hepatic encephalopathy can be discussed, 
the clinical syndrome needs definition. Hepatic encephalopathy can develop during 
acute hepatitis (which is then called fulminant hepatic failure) or during chronic liver 
disease. In the case of chronic liver disease, hepatic encephalopathy occurs in both the 
acute form (episodes) and the chronic form (chronic portosystemic encephalopathy) 
with or without exacerbations (1). Several factors have been identified that precipipate 
or enhance hepatic encephalopathy; the most important are gastro-intestinal 
hemorrhage, §.ZOtemia, which may be caused by diuretics, .§.edatives, g_onstipation, 
hypokalemic .§.lkalosis, excess intake of dietary Qrotein, .§.lcohol abuse, hepatic 
.Qarenchymal injury and infection (GASCAPAPI) (2-3). The clinical picture is independent 
of the precipitating cause and cannot be differentiated from that of other metabolic 
encephalopathies. Ultimately the problem becomes even more complex, since end-stage 
liver disease is often complicated by failure of other organ systems. 
The severity of hepatic encephalopathy is graded on a scale of 0-4 (normal to coma) on 
the basis of clinical criteria of consciousness, intellectual function, behavior and 
neuromuscular abnormalities (table 1) (1 ,3-4). The flapping tremor was initially thought 
to be specific for hepatic encephalopathy but can also occur in other conditions (3). 
Because the clinical grading system is rather subjective, objective methods of 
Table 1: Clinical grading of hepatic encephalopathy 
grade HE 
0 
2 
3 
4 
consciousness 
normal 
inverse sleep 
pattern 
hypersomnia 
insomnia 
lethargy 
stupor, pre·coma 
arousable 
coma 
intellectual 
function 
normal 
impaired calculation 
short attention span 
mild confusion 
disorientation in time 
amnesia for 
past events 
disorientation in 
place/person 
According to Zieve, Conn and Opolon (1,3-4). 
personality/ 
behavior 
normal 
depression or 
euphoria 
anxiety 
slowness 
decreased inhibition 
inappropriate 
behavior 
bizarre behavior 
incontinence 
neuromuscular 
abnormalities 
normal 
tremor 
impaired handwriting 
incoordination 
flapping tremor 
ataxia 
slurred speech 
grimacing 
hyperactive reflexes 
Babinskis 
muscle rigidity 
coordinated response, 
flexion or extension 
to painful stimuli 
~ 
~ 
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Table 2: EEG grading in hepatic encephalopathy {4-5) 
grade HE EEG characteristics 
Parsons-smith 
0 normal, regular alpha rhythm 
A suppression of alpha rhythm, 
frequent replacement by faster potentials 
generally flat and featureless 
B alpha rhythm unstable, disturbed by random waves at 5-7 c/s (most often temporal 
lobes) 
often underlying fast activity 
C alpha rhythm disturbed by 5-6 c/s waves in runs {particularly temporal and frontal) 
D 5-6 c/s rhythms constant 
E 2 c/s rhytm, preponderant frontally, spreading backwards 
Opolon 
0 
1 
2 
3 
4a 
4b 
4c 
4d 
5 
normal, regular alpha rhythm 
irregular background activity {theta and alpha rhythm) 
continuous theta activity, bursts of delta activity 
prevalent theta activity 
polyphasic transient sharp and slow wave complexes 
continous delta activity 
abundant sharp and slow wave complexes 
EEG reactivity present 
slower activity 
no reactivity 
discontinuous activity with silent periods 
rare and flat activity 
flat 
quantitation were applied, the most important being the electroencephalogram and 
psychometric tests. Parsons-Smith et al. introduced the first system for grading hepatic 
encephalopathy according to the EEG (5); later others followed (4). The fewer waves 
per second, the more severe the encephalopathy (table 2). Triphastc waves, a feature 
of the EEG often encountered in severe hepatic encephalopathy, were once described 
as diagnostic for liver disease (6), but recently similar triphasic patterns have been 
associated with other metabolic encephalopathies (7). Although the EEG is less 
subjective than clinical grading, intraobserver and interobserver errors are still 
considerable. The usefulness of quantitative EEG analysis has been demonstrated in 
longitudinal studies (8-11 ). Because the method is objective, it seems especially of 
value for scientific investigations. Psychometric testing has been proposed for the 
detection of subclinical hepatic encephalopathy (12-13). This method requires patient 
cooperation and therefore cannot be used for quantitation of the more severe stages of 
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hepatic encephalopathy (grades 2-4). 
GENERAL CONSIDERATIONS OF THE PATHOGENESIS 
Two aspects seem important to consider in a study of the pathogenesis: 
A. identification of the substrate that induces disease 
B. the mechanism of action of that substrate. 
A: Identification of the substrate 
1. Specific factors. Zieve reported 3 requirements that have to be fulfilled before a 
compound or abnormality can be considered as a causitive factor: I. it should be 
present in abnormal amounts in the presence of hepatic encephalopathy; II. induction of 
the abnormality in an animal should induce coma; and Ill. correction of the abnormality 
should reverse coma (14). The role of ammonia, especially, as a specific toxin in 
hepatic encephalopathy has been intensively investigated with reference to these 
requirements. Increased plasma ammonia levels can be found during most clinical 
episodes of hepatic encephalopathy (15). Ammonia loading in laboratory animals and 
patients with liver cirrhosis has been shown to induce encephalopathy {16-18). 
However, therapy aimed at reducing ammonia levels is not always successful as 
treatment of hepatic encephalopathy. Furthermore, investigators have argued against a 
major role for ammonia (19), because low ammonia levels have also been found in 
severe encephalopathy 120). 
2. Aspecific factors. In the past less attention has been paid to the role of 
complications, often found in severe liver disease, in the induction of encephalopathy. 
Renal failure is quite common in end-stage cirrhosis and fulminant hepatic failure (21-
22). Electrolyte abnormalities (especially hyponatremia). hypoxia and acid-base 
disturbances may all be present (1 ,23-24). Nutritional deficiencies have been reported 
in, especially, chronic liver disease (25). The observation that zinc supplementation 
improved mild hepatic encephalopathy in some studies (26-29) supports a role for zinc 
deficiency in its pathogenesis. Furthermore, infections are often encountered (23). All 
of these factors are known to induce coma when liver disease is absent (30). Because 
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both the degree and combination of these complications vary markedly in livef disease, 
their contribution to the syndrome of hepatic encephalopathy is difficult to ascertain. 
B. The mechanism of action of the substrate 
In theory, toxins or deficiencies may influence central nervous system functioning at 3 
levels {figure 1 ): 
1 . cell metabolism 
2. electrophysiologic membrane function. ion pumps maintain the concentration 
gradients of ions across the cell membrane, thereby affecting the generation and 
spreading of action potentials. 
3. biochemical communication between neurons. Neurotransmisssion can be 
excitatory or inhibitory. Excitatory neurotransmission induces depolarization 
which could lead to an action potential in a neighboring neuron. Inhibitory 
neurotransmission causes hyperpolarization of the neuron, thereby making it 
more resistant to the induction of an action potential. 
wl. 
Presynaptic 
neuron 
2. 
Postsynaptic 
neuron 
1. metabolism 
2. electrophysiological 
membrane function 
3. neurotransmission 
Figure 1: Central nervous system function: possible influences at 3 levels. Toxins or deficiencies 
may interfere with cell metabolism, electrophysiologic membrane function and 
neurotransmission. 
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The most important excitatory and inhibitory neurotransmitters in the central nervous 
system are glutamate and GABA (31), respectively. 
Direct intervention at the neuronal level opens new therapeutic possibilities. 
Furthermore, direct correction of the defect in the central nervous system will also be 
the ultimate test of the relevance of the proposed theory on pathogenesis. 
PATHOGENESIS AND IMPLICATIONS FOR THERAPY 
Ammonia 
Ammonia was the first toxin seriously considered as a factor in the pathogenesis of 
hepatic encephalopathy. It has been extensively studied with reference to the 
requirements of Zieve, as mentioned above. Ammonia was rejected as an important 
factor because poor correlations between plasma ammonia and the severity of hepatic 
encephalopathy were sometimes found (19). Furthermore, the convulsions observed in 
animals after a bolus injection of ammonia were thought to be incompatible with the 
sedation encountered in hepatic encephalopathy (19). lastly, correction of 
hyperammonemia is not always successful as treatment of hepatic encephalopathy. 
Nevertheless, correction of hyperammonemia is currently the most effective therapy we 
have. Ammonia is formed predominantly in the bowel by degradation of glutamine, 
which is used as an energy substrate in the intestinal wall, degradation of dietary 
proteins and degradation of urea by urease-producing enteric bacteria (32). Treatment 
consists of dietary protein restriction and administration of lactulose or related 
disaccharides and/or antibiotics. All treatment modalities diminish the formation of 
ammonia in the bowel. In most studies on lactulose, lactitol or the antibiotic neomycin, 
the success rate for the reversion of hepatic encephalopathy exceeded 60-70% (33). 
However, patients with nitrogen overload or patients with low-grade hepatic 
encephalopathy were usually selected for these studies. In clinical practice, therapy for 
encephalopathy in severe liver disease is often less successfuL 
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False neurotransmitter theory 
The false neurotransmitter theory, as postulated by Fischer and Baldessarini, was the 
first hypothesis for the pathogenesis of hepatic encephalopathy that explained the 
syndrome directly at the level of the central nervous system (34~35). They noticed the 
increase in the ratio of the plasma levels of the aromatic and branched chain amino 
acids, due to decreased catabolism by the liver of the aromatic and increased use in 
muscle of the branched chain amino acids. According to the theory, competition 
between the two classes of amino acids for transport across the blood brain barrier 
promotes uptake of aromatic amino acids. In the brain, the aromatic amino acids are 
decarboxylated, forming aromatic amines, and compete with Dopa for further 
metabolism. Instead of the catecholamines, false neurotransmitters (octopamine .. 
tyramine and B-phenylethanolamine) are formed. The false neurotransmitters bind to 
catecholamine receptors but then exert a minimal intrinsic effect. According to this 
theory a defect in catecholaminergic neurotransmission causes the clinical picture of 
hepatic encephalopathy. 
The theory implies two possible therapeutic strategies: 1. branched chain amino acid 
infusion to restore the plasma amino acid balance and 2. direct intervention at the level 
of neurotransmission. Many clinical studies on the effect of branched chain amino acids 
in hepatic encephalopathy have been performed. Recent reviews of these studies could 
not demonstrate an important effect, i.e. reversal of hepatic encephalopathy, although 
restoration of the amino acid balance was achieved (36-37). L-Dopa and bromocriptine, 
a synthetic dopamine agonist, were administered to enhance catecholamine 
neurotransmission directly at the neuronal level. ln acute hepatic encephalopathy no 
beneficial effect was found in a double-blind clinical trial (38). Controlled clinical trials 
on chronic portosystemic encephalopathy only indicated a positive effect of 
bromocriptine as adjuvant therapy for patients (mainly with neurological symptoms) 
who did not react to conventional therapy atone (39-40). Although rather attractive, the 
false neurotransmitter theory has therefore not been convincingly supported by direct 
intervention at the proposed neuronal level. 
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The GABA-benzodiazepine receptor theory 
The second theory explaining hepatic encephalopathy at the level of altered 
neurotransmission with direct therapeutic implications was postulated by Schafer and 
Jones (41). This theory will be discussed in more detail, in view of the studies in this 
thesis. 
Basic physiology. Gamma-aminobutyric acid (GABA) is the most important inhibitory 
neurotransmitter, accounting for 30-40% of the total neurotransmitter content in the 
brain (31 ). The GABA receptor is part of a supramolecular complex with separate 
receptor proteins for GABA, benzodiazepines and barbiturates (figure 1) (42-43). After 
the binding of GABA to its receptor, the chloride ionophore which is coupled to the 
GABA receptor opens and chloride ions diffuse into the cell, thereby causing 
hyperpolarization of the neuronal membrane (42). The binding of GABA to its receptor 
and thus its inhibitory action is modulated by the binding of benzodiazepine ligands to 
their own receptor on the same supramolecular complex. Benzodiazepine agonists 
PICROTOXININ 
BARBITURATE 
SITE 
CHLORIDE 
CHANNEL 
GABA-R 
CELL MEMBRANE 
BZR 
1 r r 
l l l 
Figure 2: GABA-benzodiazepine receptor complex with binding sites for GABA (GABA-RJ and 
benzodiazepines (BZR); the GABA receptor is coupled to a chloride ionophore (from: Bruun-
Meyer SE. The GABA/benzodiazepine receptor-chloride ionophore complex: nature and 
modulation. Progr Neuropsychopharmacol Bioi Psychiatr 1987;4:365-387). 
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enhance the binding of GABA to its receptor, whereas inverse agonists diminish it. 
Newly developed benzodiazepine antagonists, such as f!umazenil, inhibit the binding of 
benzodiazepine agonists and inverse agonists but are not considered to have an 
intrinsic effect on their own (figure 3, table 3) (43). 
The "GABA-theory" for the pathogenesis of hepatic encephalopathy implies elevated 
serum concentrations of gut-derived GABA, increased permeability of the blood brain 
barrier to facilitate passage of GABA into the central nervous system and an increased 
number of brain GABA and benzodiazepine receptors, which make the brain 
hypersensitive to the effect of GABA and benzodiazepines (41 ). The theory was 
supported by the finding of increased concentrations of GABA-Iike activity in serum 
(44), enhanced transfer of a-aminobutyric acid and GABA across the blood brain barrier 
INTRINSIC 
ACTIVITY: 
AGONISTS COMPETITIVE INVERSE 
ANTAGONiSTS AGONJSTS 
H H3~ 0 
r N)o N OS ( fcooc 2H5 n; H3CO CJ F ~ o2N H3Co 0 CH 3 
+++ 0 
Clonazepam Ro 15-1788 OMCM 
~~~ 
 
( 6ENZO. \ 
+ RECEPTOR 
GABA 
RECEPTOR 
o, 
CH 3 
Figure 3: Interaction of the different benzodiazepine ligands with the benzodiazepine receptor 
and their subsequent influence on the binding of GABA to its receptor (from: Richards JG, 
Schoch P, MOhler H, Haefely W. Benzodiazepine receptors resolved. Experientia 1986;42:121-
126). 
Table 3: Benzodiazepine receptor ligands 
Benzodiazepine receptor agonists 
diazepam, 
N-desmethyldiazepam 
clonazepam 
oxazepam 
midazolam 
Benzodiazepine receptor antagonists 
flumazenil (Ro 15-1788) 
CGS 8216 
Benzodiazepine receptor inverse agonists 
OMCM (methyl-6, 7-dimethoxy-4-ethyi-
B-carboline-3-carboxylate) 
diazepam bound inhibitor (OBI) 
octa-decaneuropeptide {ODN) 
B-CCB (butyi-B-carboli:ne-3-carboxylate) 
B-CCE (ethyi-B-carboline-3-carboxylatel 
RO 15-3505 (partial inverse activities) 
RO 15-4513 (partial inverse activities) 
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(45-46) and increased binding of GABA and flunitrazepam to cerebral synaptosomal 
membranes in galactosamine-treated rabbits (47). Furthermore, visual evoked potentials 
were similar for rabbits treated with muscimol, a GABA agonist, or diazepam, a 
benzodiazepine agonist, and rabbits with galactosamine-induced liver failure (48). 
However, the use of visual evoked potentials for studies on pathogenesis, thereby 
suggesting specificity of the method, has seriously been questioned (49-50). 
Furthermore, a study on visual evoked potentials in a rat model revealed differences in 
the VEP pattern during hepatic encephalopathy and after treatment with a GABA-
mimetic drug (51). Confirmation of all other supportive evidence for the theory also 
could not be achieved. The GABA-receptor assay, used in the first clinical (44) and 
experimental (52-53) studies to measure plasma GABA levels, was found to 
overestimate the true levels of GABA as measured by HPLC due to interference of 
taurine and glutamine (54-55). Nevertheless, HPLC studies still revealed elevated GABA 
levels in clinical (56) as well as experimental (54,57) acute and chronic hepatic 
encephalopathy, but these findings contradicted the results of mass-fragmentography 
(58-59). 
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The concept of the increased permeability of the blood brain barrier for GABA, originally 
demonstrated in the galactosamine rabbit model of acute hepatic failure (45-46}, also 
could not be confirmed in other animal models of acute or chronic hepatic 
encephalopathy (60-62). The only study confirming increased permeability for GABA 
concluded that it was an unspecific alteration in end-stage multi-organ failure (63). 
Furthermore, the idea that elevated plasma GABA concentrations induce elevated brain 
levels is not supported by the findings of normal GABA concentrations in cerebrospinal 
fluid in chronic hepatic encephalopathy (59,64-65), normal cerebral GABA 
concentrations in acute and chronic experimental hepatic encephalopathy (58,60) and 
normal post-mortem GABA concentrations in brains from patients with acute and 
chronic liver disease (66-67). Direct analysis of the extracellular brain fluid by in-vivo 
brain dialysis, to evaluate neurotransmitter access to neuronal synapses, also revealed 
normal GABA levels in portocaval shunted rats (68). 
Further studies on the number of cerebral GABA receptors raised even more doubts on 
the significance of the GABA hypothesis. An increase in GABA receptors could be 
demonstrated in only 4 (47 ,69-71) of the 18 reported experimental studies on acute 
and chronic hepatic encephalopathy (47,52-53,57,60,69-79). Similarly, recent 
experimental studies on the number of benzodiazepine receptors (57 ,77) contradicted 
previous studies describing increased numbers (47 ,80). GABA and benzodiazepine 
receptor binding in brain tissue taken at autopsy from cirrhotic patients with hepatic 
encephalopathy was found to be unchanged in two studies (81-82); one study 
demonstrated unchanged numbers but an altered affinity of the GABA receptors (83). 
Recently, the finding of increased numbers of GABA and benzodiazepine receptors in 
the galactosamine rabbit model was retracted (84). 
Therapy with a benzodiazepine antagonist. With the GABA theory fading, the concept 
of an endogenous benzodiazepine agonist that could cause hepatic encephalopathy was 
postulated (85). In a few case reports flumazenil, the first benzodiazepine antagonist in 
clinical practice, was said to ameliorate clinical hepatic coma {86-87). Furthermore, 
several benzodiazepine antagonists were found to be beneficial in rabbits and rats with 
acute hepatic failure due to galactosamine and thioacetamide (80,88-90). Because it is 
assumed that benzodiazepine antagonists do not have an intrinsic effect, a beneficial 
effect indeed points to the presence of endogenous benzodiazepine-like compounds. 
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Further evidence for the existence of a natural benzodiazepine ligand was obtained from 
in vitro electrophysiological studies on cerebellar membranes and radioreceptor assays 
of brain homogenates from rabbits and rats with toxin-induced liver failure (91-92). 
However, experimental studies on benzodiazepine antagonists also yielded negative 
results, particularly in rats with acute ischemic liver failure (93-94). Controversial 
findings were obtained on the effect of a partial inverse benzodiazepine agonist and a 
GABA receptor antagonist in this animal model (94-95). 
In uncontrolled clinical studies on flumazenil for hepatic encephalopathy remarkably 
high success rates have been reported: in the two largest studies response rates of 60-
Table 4: Clinical studies on flumazenil for hepatic encephalopathy 
episodes studied 
effect 
screening 
author, ref nr total :S1.0mg1 >1.0 mg1 no effect Bz 
cirrhosis 
Bansky, 87 4 2 2 N 
Bansky, 96 14 10 4 y 
Grimm, 97 9 6 3 ± 
Meier, 98 4 3 1 y 
Klotz, 99 2 2 y 
Ferenci, 1 00 1 1 y 
Pidoux, 101 6 4 Y' 
Viel, 102 3 2 y 
acute hepatic failure 
Grimm, 97 11 4 2 5 ± 
Pidoux, 101 1 N 
Sutherland, 1 03 N 
unknown liver disease 
Scollo-Lavizzari, 86 N 
Burke, 104 N 
total 58 26 12 20 
no reversal 
HE after bolus 6 
Bz=benzodiazepine; Y=screening of plasma and/or urine was performed; N=no screening of 
plasma and/or urine was mentioned; ±=some of the patients were tested. 
1. dose of flumazenil studied; 2. at least 3 patients had used benzodiazepines. 
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71% were found (96-97); considering all episodes studied, an effect occurred in 66% 
(table 4) (86-87 ,96-1 04}. Antagonism of previously used synthetic benzodiazepines has 
been suggested (99). Some authors reported the previous use of these drugs (101), 
while others applied insensitive methods to screen for benzodiazepines in plasma or 
urine (97). Controlled studies on the effect of flumazenil are needed and particular 
attention should be directed toward the relation between a response to f!umazenil and 
the previous use of benzodiazepines as detected by history and laboratory screening 
methods. 
AIMS OF THE STUOY 
1. To develop an objective method for measurement of the depth of hepatic 
encephalopathy for studies on its pathogenesis and therapy 
2. to study the effect of f[umazenil on hepatic encephalopathy 
3. to evaluate the contribution of aspecific factors to the induction of hepatic 
encephalopathy. 
REFERENCES 
1. Zieve l. Hepatic encephalopathy. In: Schiff L, Schiff ER. Diseases of the liver. JB. 
Lippincott Company, Philadelphia-Toronto 1985. 
2. Faloon WW, Evans GL. Precipitating factorS in genesis of hepatic coma. NY State J Med 
1970;70:2891-2896. 
3. Conn HO. The hepatic encephalopathies. In: Conn HO, Bircher J. Hepatic 
encephalopathy: management with lactulose and related carbohydrates. Medi-Ed Press, 
East Lansing, Michigan 1988:3-14. 
4. Opolon P, Rapin JR, Huguet C, Granger A, Delorme ML, Boschat M, Sausse A. Hepatic 
failure coma treated by polyacrylonitrile membrane hemodialysis. Trans Am Soc Artif 
Intern Organs 1976;22: 701-711. 
5. Parsons-Smith BG, Summerskill WHJ, Dawson AM, Sherlock S. The 
electroencephalogram in liver disease. Lancet 1957,ii:867-871. 
6. Bickford RG, Butt HR. Hepatic coma: the electro-encephalographic pattern. J Clin Invest 
1955;34:790-799. 
23 
7. Fisch BJ, Klass DW. The diagnostic specificity of triphasic wave patterns. 
Electroencephalogr Clin Neurophysiol 1988;70:1-8. 
8. Laidlaw J, Read AE. The electroencephalographic diagnosis of manifest and latent 
"delirium" with particular reference to that complicating hepatic cirrhosis. J Neural 
Neurosurg Psychiatry 1961 ;24:58-70. 
9. Hawkes CH, Macpherson AJS, Pryor H, Townsend HRA. The values of EEG frequency 
analysis in hepatic encephalopathy. J R Coli Surg Edinb 1970;15:151-156. 
10. Holm E, Thiele H, Wolpert EM, Heim ME, Reimann-Werle B. Neurologische und 
psychiatrische Symptome bel akuten und chronischen lebererkrankungen. 
Therapiewoche 1980;30:4790-4806. 
11. Yaar J, Shapiro MB, Pottala EW. Spectral analysis of the EEG in hepatic encephalopathy 
treated with levodopa. Electroencephalogr Clin Neurophysiol 1981 ;52:617-625. 
12. Conn HO. Trailmaking and number connection test in the assessment of mental state in 
portal systemic encephalopathy. Am J Dig Dis 1977;22:541-550. 
13. Gilberstadt SJ, Gilberstadt H. Psychomotor performance defects in cirrhotic patients 
without overt hepatic encephalopathy. Arch Intern Med 1980;140:519-521. 
14. Zieve L. The mechanism of hepatic coma. Hepatology 1981 ;1 :360-365. 
15. Stahl J. Studies of the blood ammonia in liver disease. Its diagnostic, prognostic, and 
therapeutic significance. Ann Intern Med 1963;58:1-24. 
16. Fick TE, Schalm SW, De Vlieger M. A surgical model of fulminant hepatic failure in the 
rabbit: different effects of end-to-side versus small-diameter side-to-side portacaval 
shunt. Eur Surg Res 1987;19:276-282. 
17. Matthews SA. Ammonia, a causitive factor in meat poisoning in Eck fistula dogs. Am J 
Physiol 1922;59:459-460. 
18. Philips GB, Schwartz R, Gabuzda GJ, Davidson CS. The syndrome of impending hepatic 
coma in patients with cirrhosis of the liver given certain nitrogenous substances. N Eng! 
J Med 1952;247:239-246. 
19. Jones EA. The enigma of hepatic encephalopathy. Postgrad Med J 1983;59:42-54. 
20. Phear EA, Sherlock S, Summerskill WHJ. Blood-ammonium levels in liver disease and 
"hepatic coma". Lancet 1955;i:836-840. 
21. Bilhari DJ, Gimson AES, Williams R. Cardiovascular, pulmonary and renal complications 
of fulminant hepatic failure. Seminars in liver disease. 1986;6:119-128. 
22. Ring-Larsen H, Palazzoll U. Rena! failure in fulminant hepatic failure and terminal 
cirrhosis: a comparison between incidence, types and prognosis. Gut 1981 ;22:585-591. 
23. Ward ME, Trewbye PN, Williams R, Strunin L. Acute liver failure. Experience in a special 
unit. Anaesthesia 1977;32:228-239. 
24. Oster JR. Acid-base homeostasis and liver disease. In: Epstein M. The kidney in liver 
24 
disease, 2nd edition. Elsevier Science Publishing Co, New York 1983;147-187. 
25. Morgan MJ, Mcintyre N. Nutritional aspects of liver disease in liver and biliary disease. 
ln: Wright R, Millward-Sadler GH, Alberti KGMM, Karren S. Balliere Tindall WB, 
Saunders Company, London 1985. 
26. Reding P, Duchateau J, Batai!le C. Oral zinc supplementation improves hepatic 
encephalopathy. Results of a randomised controlled trial. lancet 1984;2:493-495. 
27. Sch61merich J, langenberger G, Steiert B, LOhle E, Wokalek H, Tauber R, K6ttgen E, 
Gerok W. Long term zinc substitution in patients with zinc deficiency in liver cirrhosis 
(Abstract}. Gastroenterology 1986;90:1765. 
28. Lambert JR, Provis-Vincent M, Korman MG, Hansky J. Zinc status in cirrhosis and 
hepatic encephalopathy (Abstract). Gastroenterology 1987;92:1479. 
29. Couinaud C. Traitement de l'encephalopathie porto-systemique aigue par le zinc. 
Chirurgie 1985; 111 :575-579. 
30. Plum F, Posner JB. The diagnosis of stupor and coma. FA Davis Company, Philadelphia 
1985. 
31. Walker JE. Glutamate, GABA and CNS disease: a review. Neurochem Res 1983;8:521-
550. 
32. Bode JCh, Schafer K. Pathophysiology of chronic hepatic encephalopathy. 
Hepatogastroentero/ogy 1 985;32:259-266. 
33. Orlandi F, Brunelli E, Benedetti A, Macarri G. Clinical trials of lactulose therapy in 
hepatic encephalopathy. In: Conn HO, Bircher J. Hepatic encephalopathy: management 
with lactulose and related carbohydrates. Medi-Ed Press, East Lansing, Michigan 
1988:191-198. 
34. Fischer JF. Baldessarini RJ. False neurotransmitters and hepatic failure. Lancet 
1971 ;ii:75-80. 
35. James JH, Jeppsson B, Ziparo V, Fischer JF. Hyperammonaemia, plasma aminoacid 
imbalance, and blood-brain aminoacid transport: a unified theory of portal-systemic 
encephalopathy. Lancet 1979;ii:772-775. 
36. Erikson LS, Conn HO. Branched-chain amir.o acids in the management of hepatic 
encephalopathy: an analysis of variants. Hepatology 1 989; 1 0:228-246. 
37. Morgan MY. Branched chain amino acids in the management of chronic liver disease. 
Facts and fantasies. J Hepatol 1990;11: 133-141. 
38. Michel H. Treatment of cirrhotic hepatic encephalopathy with L-Dopa. A controlled trial. 
Gastroenterology 1980;79:207-211. 
39. Uribe M, Farca A, Marquez MA, Garda-Ramos G, Guevara l, Briones A, Gil S. 
Treatment of chronic portal systemic encephalopathy with bromocriptine. A double-blind 
controlled trial. Gastroenterololy 1979;76:1347-1351. 
25 
40. Morgan MY. Successful use of bromocriptine in the treatment of chronic hepatic 
encephalopathy. Gastroenterology 1980;78:663-670. 
41. Schafer OF, Jones EA. Hepatic encephalopathy and the gamma-aminobutyric-acid 
neurotransmitter system. Lancet 1982;ii:18-20. 
42. Ticku MK. Benzodiazepine-GABA receptor ionophore complex. Current concepts. 
Neuropharmaco!ogy 1 983;22:1459-1470. 
43. Braestrup C, Nielsen M, Honore T, Jensen LH, Petersen EN. Benzodiazepine ligands with 
positive and negative efficacy. Neuropharmacology 1983;22: 1451-1457. 
44. Ferenci P, Kleinberger G, Schafer DF, Hoofnag!e JH, Jones EA. Serum levels of gamma-
aminobutyric-acid-!ike activity in acute and chronic hepatocellular disease. Lancet 
1983;;;:811-814. 
45. Horowitz ME, Schafer DF, Molnar P, Jones EA, Blasberg RG, Patlak CS, Waggoner J, 
Fenstermacher JD. Increased blood-brain transfer in a rabbit model of acute liver faHure. 
Gastroenterology 1983;84: 1 003-1 011. 
46. Bassett ML, Mullen KD, Scholz B, Fenstermacher JD, Jones EA. Increased brain uptake 
of gamma-aminobutyric acid in a rabbit model of hepatic encephalopathy. 
Gastroenterology 1990;98:747-757. 
47. Schafer OF, Fowler JM, Munson PJ, Thakur AK, Waggoner JG, Jones EA. Gamma-
aminobutyric acid and benzodiazepine receptors in an animal model of fulminant hepatic 
failure. J Lab C!in Med 1983;1 02:870-880. 
48. Schafer OF, Pappas SC, Brody LE, Jacobs R, Jones EA. Visual evoked potentials in a 
rabbit model of hepatic encephalopathy. I. Sequential changes and comparisons with 
drug-induced comas. Gastroenterology 1 984;86:540-545. 
49. Raabe WA. Hepat;c encephalopathy and GABA. Lancet 1982;;:1 020-1021. 
50. Myslobodsky MS. Gamma-aminobutyric acid {GABAJ and hepatic encephalopathy: 
testing the validy of electroencephalographic evidence of the GABA hypothesis. 
Hepatogastroenterotogy 1987;34:58-64. 
51. Zeneroli ML, Ventura E, Baraldi M, Penne A, Messori E, Zieve L. Visual evoked 
potentials in hepatic encephalopathy induced by galactosamine, ammonia, 
dimethy!disulfide, and octanoic acid. Hepatology 1982;2:532-538. 
52. Maddison JE, Dodd PR, Johnston AR, Farrell GC. Brain gamma-aminobutyric acid 
receptor binding is normal in rats with thioacetamide-induced hepatic encephalopathy 
despite elevated plasma gamma-aminobutyric acid-like activity. Gastroenterology 
1 987;93:1 062-1068. 
53. Thompson JS, Schafer OF, Schafer GJ, Hodgson FE. Gamma-aminobutyric acid plasma 
levels and brain binding in eck fistula dogs. J Surg Res 1985;38:143-148. 
54. Maddison JE, Leong DK, Dodd PR, Johnston GAR. Plasma GABA-Iike activity in rats 
26 
with hepatic encephalopathy is due to GABA and taurine. Hepatology 1990;11 :105-
110. 
55. Ferenci P, Ebner J, Zimmermann C, Kikuta C, Roth E, Haussinger D. Overestimation of 
serum concentrations of gamma-aminobutyric acid in patients with hepatic 
encephalopathy by the gamma-aminobutyric acid-radioreceptor assay. Hepatology 
1988;8:69-72. 
56. Minuk G, Winder A, Burgess ED, Sarjeant EJ. Serum gamma-aminobutyric acid (GABA} 
levels in patients with hepatic encephalopathy. Hepatogastroenterology 1985;32:171-
174. 
57. Maddison JE, Dodd PR, Morrison M, Johnston GAR, Farrell GC. Plasma GABA, GABA-
Iike activity and the brain GABA-benzodiazepine receptor complex in rats with chronic 
hepatic encephalopathy. Hepatology 1987;7:621 ~628. 
58. Zeneroli Ml, Iuliano E, Racagni G, Baraldi M. Metabolism and brain uptake of gamma-
aminobutyric acid in galactosamine~induced hepatic encephalopahty in rats. J 
Neurochem 1982;38:1219~1222. 
59. Moroni F, Riggio 0, Carla V, Festuccia V, Ghinelii F, Marino IR, Merli M et al. Hepatic 
encephalopathy: lack of changes of gamma~aminobutyric acid content in plasma and 
cerebrospinal fluid. Hepatology 1987;7:816~820. 
60. Roy S, Pomier~Layrargues G, Butterworth RF, Huet P.M. Hepatic encephalopathy in 
cirrhotic and portacaval shunted dogs: lack of changes in brain GABA uptake, brain 
GABA levels, brain glutamic acid decarboxylase activity and brain postsynaptic GABA 
receptors. Hepatology 1988;8:845~849. 
61. Knudsen GM, Poulsen HE, Paulson 08. Blood~brain barrier permeability in galactosamine-
induced hepatic encephalopathy. No evidence for increased GABA~transport. J Hepatol 
1988;6:187-192. 
62. Lo WD, Ennis SR, Goldstein GW, McNeely Dl, Betz AL. The effects of galactosamine~ 
induced hepatic failure upon blood-brain barrier permeability. Hepatology 1987;7:452~ 
456. 
63. Van Serlo CLH, Van den Bogaard AEJM, Kelderman PHMW, Van Dongen JJ, Van der 
Heijden MAH, Soeters PB. Comparison of blood~brain transfer of alpha~aminoisobutyric 
acid (AlB) in rabbit models of acute and chronic liver disease and acute organ ischemia. 
In: Soeters PB, Wilson JHP, Meijer AJ, Holm E. Advances in ammonia metabolism and 
hepatic encephalopathy. Proceedings of the 6th international symposium on ammonia, 
Vaalsbroek Castle, The Netherlands, 27~29 April 1987. Amsterdam: Elsevier Science 
Publishers B.V., 300~308. 
64. Maddison JE, Yau 0, Stewart P, Farrell GC. Cerebrospinal fluid gamma-aminobutyric 
acid levels in dogs with chronic portosystemic encephalopathy. Clin Sci 1986;71 :749~ 
27 
753. 
65. Riggio 0, Moroni F, Capocaccia L, Merli M, Ariosto F, Varriale M, Pieche U, et al. 
Plasma and cerebrospinal fluid gamma-aminobutyric acid in cirrhotic patients with 
hepatic encephalopathy. In: Soeters PB, Wilson JHP, Meijer AJ, Holm E. Advances in 
ammonia metabolism and hepatic encephalopathy. Proceedings of the 6th international 
symposium on ammonia, Vaalsbroek Castle, The Netherlands, 27-29 April 1987. 
Amsterdam: Elsevier Science Publishers B.V., 314-318. 
66. Record CO, Plasma and brain amino acids in fulminant hepatic failure and their 
relationship to hepatic encephalopathy. Eur J Clin Invest 1976;6:387-394. 
67. Lavoie J, Giguere JF, Pomier layrargues G, Butterworth RF. Amino acid changes in 
autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. J Neurochem 
1987;49:692-697. 
68. Tessman U, Brain amino acids measured by intracerebral dialysis in portacaval shunted 
rats. J Neurochem 1983;41: 1 046-1 051. 
69. Baraldi M, Zeneroli ML. Experimental hepatic encephalopathy: changes in the binding of 
gamma-aminobutyric acid. Science 1982;216:427-429. 
70. Baraldi M, Zeneroli Ml, Ventura E, Pinelli G, Ricci P, Santi M, Racagni G, et al. Portal-
systemic encephalopathy in dogs: changes in brain GABA-receptors and neurochemical 
correlates. In: Kleinberger G, Ferenci P, Riederer P, Thaler H. Advances in hepatic and 
urea cycle diseases. 5th international symposium on ammonia, Semmering, Austria, 
May 16·19, 1 984. Basel: S. Karger, 1984;353·359. 
71. Pappas SC, levy G, Gordon VP, Nakatsukasa H, Martin P. The GABA hypothesis of 
hepatic encephalopathy: further studies in multiple animal models. In: Soeters PB, 
Wilson JHP, Meijer AJ, Holm E. Advances in ammonia metabolism and hepatic 
encephalopathy. Proceedings of the 6th international symposium on ammonia, 
Vaalsbroek Castle, The Netherlands, 27-29 April 1987. Amsterdam: Elsevier Science 
Publishers B.V., 259-264. 
72. Wysmyk-Cybula U, Dabrowiecki Z, Albrecht J. Changes in the metabolism and binding 
of GABA in the rat brain in thioacetamide-induced hepatogenic encephalopathy. Biomed 
Biochim Acta 1986;3:413-419. 
73. Ferenci P, Zieve L, Ebner J, Zimmermann Ch, Rzepczynski D. Postsynaptic gamma-
aminobutyric acid receptors in hepatic coma following portacaval shunt and hepatic 
artery ligation in the rat. Metab Brain Dis 1987;2:195-200. 
74. Nakatsukasa H, Gordon VP, Martin P, Pappas SC. Brain gamma-aminobutyric acid 
(GABA) binding is unaltered in two guinea pigs models of fulminant hepatic 
failure:further evidence conflicting with the GABA hypothesis (Abstract). Hepatology 
1987;7:1033. 
28 
75. Watanabe A, Fujiwara M, Shiota T, Tsuji T. Amino acid neurotransmitters and their 
receptors in the brain synaptosomes of acute hepatic failure rats. Biochem Med Metab 
s;ot 1988;40:247-252. 
76. Zanchin G, Maggioni F, Salassa 0, Vassanelli P. GABA and dopamine receptors after 
chronic porta-caval shunt in the rat. In: Kleinberger G, Ferenci P, Riederer P, Thaler H. 
Advances in hepatic and urea cycle diseases. 5th international symposium on ammonia, 
Semmering, Austria, May 16-19, 1984. Basel: S. Karger, 360-367. 
77. Ferenci P, Zimmermann Ch, Ebner J. Gamma-aminobutyric acid (GABA)-ergic and 
glutamatergic neurotransmission in hepatic encephalopathy (HE) in thio-acetamide 
(TAA)-induced liver failure in rats (Abstract). Hepatology 1987;7:1 033. 
78. Maddison JE, Dodd PR, Morrison M, Johnston GAR, Farrell GC. Plasma GABA 
concentrations and cerebro·cortical GABA receptor binding and function in dogs with 
congenital portosystemic encephalopathy (Abstract). J Hepatol 1987;4(Suppl.1 ):S29. 
79. Giguere JF, Besnard AM, Fournier H, Bergeron M, Butterworth RF. Evidence for a 
functional imbalance beteen central GABAergic and glutamatergic neurotransmission on 
portal-systemic encephalopathy (Abstract). J Hepatol 1987;4(Supp!. 1):820. 
80. Baraldi M, Zeneroli ML, Ventura E et al. Supersensitivity of benzodiazepine receptors in 
hepatic encephalopathy due to fulminant hepatic failure in the rat: reversal by a 
benzodiazepine antagonist. Clin Sci 1984;67: 167-175. 
81. Butterworth RF, Lavoie J, Giguere JF, and Pomier-layrargues G. Affinities and densities 
of high-affinity [3 H]muscimol (GABA-A) binding sites and of central benzodiazepine 
receptors are unchanged in autopsied brain tissue from cirrhotic patients with hepatic 
encephalopathy. Hepatoiogy 1988;8:1 084-1088. 
82. Lal S, Quirion R, Lafaille F, Nair NPV, Loo P, Braunwalder A, Wood P, Williams M. 
Muscarinic, benzodiazepine, GABA, chloride channel and other binding sites in frontal 
cortex in hepatic coma in man. Prog Neuropsychopharmacol Bioi Psychiatry 
1987;11 :243-250. 
83. Ferenci P, Riederer R, Jellinger K, Schafer D, Jones EA. Changes in cerebral receptors 
for gamma aminobutyric acid in patients with hepatic encephalopathy. Liver 
1988;8:225-230. 
84. ROssie M, Deckert J, and Jones EAJ. Autoradiographic analysis of GABA-benzodiazepine 
receptors in an animal model of acute hepatic encephalopathy. Hepatology 
1989;10:143-147. 
85. Mullen KD, Martin JV, Mendelson WB, Bassett ML, Jones EA. Could an endogenous 
benzodiazepine ligand contribute to hepatic encephalopathy? Lancet 1988;1 :457-459. 
86. Scollo-Lavizzari G, Steinmann E. Reversal of hepatic coma by benzodiazepine antagonist 
Ro15-1788. Lancet 1985;1:1324. 
29 
87. Bansky G, Meier PJ, Ziegler WH, Walser H, Schmid M, Huber M. Reversal of hepatic 
coma by benzodiazepine antagonist Ro15-1788. Lancet 1985;1 :1324-1325. 
88. Bassett ML, Mullen KD, Skolnick P, Jones EA. Amelioration of hepatic encephalopathy 
by pharmacologic antagonism of the GABA-A-Benzodiazepine receptor complex in a 
rabbit model of fulminant hepatic failure. Gastroenterology 1987;93:1 069-1 077. 
89. Zeneroli ML, Baraldi M. Increased functional activity of the GABA-benzodiazepine 
receptor unit in a rat model of hepatic encephalopathy: pharmacological evidence 
(Abstract). Hepatology 1988;8: 1388. 
90. Gamma! SH, Basile AS, Geller D, Skolnick P, Jones EA. Reversal of the behavioral and 
electrophysiologa! abnormalities of an animal model of hepatic encephalopathy by 
benzodiazepine receptor ligands. Hepatology 1990;11:371-378. 
91. Basile AS, Gamma! SH, Mullen KD, Jones EA, Skolnick P. Differential responsiveness of 
cerebellar Purkinje neurons to GABA and benzodiazepine receptor ligands in an animal 
model of hepatic encephalopathy. J Neurosci 1988;8:2414-2421. 
92. Basile AS, Gamma! SH, Jones EA, Skolnick P. GABAA receptor complex in an 
experimental model of hepatic encephalopathy: evidence for elevated levels of an 
endogenous benzodiazepine receptor ligand. J Neurochem 1989;53:1 057-1063. 
93. Zieve L, Ferenci P, Rzepczynski D, Ebner J, Zimmermann C. A Benzodiazepine 
antagonist does not alter the course of experimental hepatic encephalopathy or neural 
gamma-aminobutyric acid (GABA) binding. Metab Brain Dis 1987;2:201-205. 
94. Bosman DK, Maas MAW, Van den Buijs CACG, Chamuleau RAFM. The effects of 
benzodiazepine receptor (BZR) antagonist and BZR inverse agonist on acute hepatic 
encephalopathy (HE) in the rat (Abstract). J Hepatol 1989;9 (suppt.1 ):S1 0. 
95. Rzepczynski D, Zieve L, Lindblad S, LaFontaine D. In vivo studies of GABAergic effects 
in experimental hepatic encephalopathy. Hepatology 1986;6:902-905. 
96. Bansky G, Meier PJ, Riederer E, Walser H, Ziegler WH, Schmid M. Effects of the 
benzodiazepine receptor antagonist flumazenit in hepatic encephalopathy in humans. 
Gastroenterology 1 989;97:44-50. 
97. Grimm G, Katzenschlager R, Schneeweiss B, Lenz K, Ferenci P, Madl C, Laggner AN et 
al. Improvement of hepatic encephalopathy treated with flumazenil. Lancet 
1988; 11 :1392-1394. 
98. Meier R. Gyr K. Therapie der hepatischen Enzephalopathie (HE) mit dem Benzodiazepin-
Antagonisten Flumazenil-Pilotstudie (abstract). Z Gastroenterol 1988;26:545. 
99. Klotz U, WalkerS. Flumazenil and hepatic encephalopathy. Lancet 1989;1 :155-156. 
100. Ferenci P, Grimm G, Meryn S, Gangl A. Successful long-term treatment of portal-
systemic encephalopathy by the benzodiazepine antagonist flumazeni!. Gastroenterology 
1989;96:240-243. 
30 
101. Pidoux B, Zylberberg P, Valla D, Opal on P. Etude electro~encephalographique de l'effet 
d'un antagoniste des benzodiazepines dans l'encephalopathie hepatique. Neurophysiol 
CJ;n 1989;19:469-476. 
102. Viel E, de La Coussaye JE, Bassoul 8, Saissi G, Eledjam JJ. Traitement de 
l'enc8phalopathie h8patique aigue par le flumazenil. Ann Fr Anesth Reanim 1990;9:386w 
389. 
103. Sutherland LR, Minuk GY. Ro15-1788 and hepatic failure. Ann Intern Med 
1988;108:158. 
1 04. Burke DA. Reversal of hepatic coma with flumazenil with improvement in visual evoked 
potentials. Lancet 1988; 11 :505-506. 
Chapter 2 
OBJECTIVE MEASUREMENT OF HEPATIC ENCEPHAlOPATHY 
BY MEANS OF AUTOMATED EEG ANAlYSIS. 
The contents of this chapter have been published in: 
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Electroencephalography and Clinical Neurophysiology (1984,57:423-426) under the 
same title with the following authors: C. C. D. van der Rijt, S.W. Schalm, G.H. de Groot, 
M. de Vlieger {part one), and 
Progress in hepatic encephalopahty and metabolic nitrogen exchange, A. Bengtsson, 
Jeppsson 8, Almdal TH, Vilstrup H (Ed.), CRC Press, Boca Raton, USA (1991 ;59-66) 
under the title Spectral Analysis in Hepatic Encephalopathy with the following authors: 
C.C.D. van der Rijt, S.W. Schalm (part two). 
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ABSTRACT 
Automated analysis of the electroencephalogram as an objective measurement of 
hepatic encephalopathy for the individual patient was investigated. In part one of the 
study the parameters mean dominant frequency, relative delta and relative theta 
activity were investigated. The mean dominant frequency of patients with grade 0 and 
1 hepatic encephalopathy was in the normal range ( ~ 6.4 Hz); grade 1 hepatic 
encephalpathy, however, was characterized by abnormal relative power of theta 
activity of more than 35%. Twelve out of 34 patients with clinical grade 0 hepatic 
encephalopathy also had an elevated power of theta activity and probably therefore 
latent hepatic encephalopathy. Patients with grades 2, 3 and 4 hepatic encephalopathy 
had a low mean dominant frequency ( < 6.4 Hz) and could be identified by a biphasic 
power spectrum {theta and delta peaks, grade 2) or by a high power of delta activity 
(;;::: 70%, grade 3-4). In part two of the study the contributary value of the total power 
was investigated, especially for the differentiation between grades 3 and 4 hepatic 
encephalopathy. Grade 3 encephalopathy was characterized by a high total power 
( > 250 pV2 ) and could be further differentiated from the grades 2 and 4. We conclude 
that automated EEG analysis based on the parameters mean dominant frequency, 
relative powers of the delta and theta bands and the total power is very suitable for 
objective classification of hepatic encephalopathy in individual patients. 
PART ONE 
Methods for the objective measurement of hepatic encephalopathy (HE) are badly 
needed, in particular for studies of its pathogenesis and evaluation of its treatment. 
Clinical grading (1 ), psychometric tests (2) and conventional electroencephalography 
(1 ,3) have been used for the assessment, but these methods are characterized by 
considerable inter- and intraobserver error. Quantitative EEG analysis has been shown 
useful in longitudinal studies of hepatic encephalopathy (4-7). Precise classification of 
individuals for the degree of encephalopathy by quantitative EEG analysis has not been 
described. Therefore we investigated the discriminatory value of the mean dominant 
frequency and of the so-called "power spectrum" in controls and patients with the 
different grades of hepatic encephalopathy. 
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MATERIALS AND METHODS 
The study population comprised a group of 51 normal controls (median age 41 years, 
range 21-78) and a group of 66 patients with histologically confirmed cirrhosis of the 
liver (median age 60 years, range 21-75). The cirrhotic patients were seen by two 
independent physicians who assessed the clinical grade of hepatic encephalopathy (1 ); 
only patients with identical scores were included in the study. Thirty-four patients {age 
range 28-75 years) presented with grade 0, seven (45-73 years) with grade 1, thirteen 
(52-75 years) with grade 2, five (57-71 years) with grade 3, and seven (21-47 years) 
with grade 4. 
During the investigation the patient lay in a quit room with eyes closed, but fully 
awake. When sleepiness was observed, an auditory stimulus was applied by the EEG 
technician, who carefully followed the the recording. Later the EEG record was seen by 
an electroneurologist and only records without technical artifacts and without evidence 
of sleepiness were accepted for analysis. The electrodes were placed according to the 
1 0-20 system. During 3 epochs of 1 00 sec the variations in electric potential between 
0.53 and 70 c/sec in leads T4-02 and T3-01 (tempero-occipital) were registered by an 
8-channe[ EEG apparatus and stored on magnetic tape. 
Subsequently the data were fed into a computer (PDP 11 /34) at a sampling rate of 
51.2 Hz and a sensitivity of 11 bits/5 V. To avoid aliasing (interference of high-
frequency energy), the signals were filtered at 25.6 Hz. Each epoch of 100 sec was 
divided into 10 periods. The power spectrum was calculated for each period of 10 sec 
using Fast Fourier Transformation and subsequently the mean power spectrum for each 
100 sec epoch was constructed. The frequency resolution was 0.1. 
The parameters calculated for the range 1-25.6 Hz (to minimize the effect of slow eye 
movements) were the mean dominant frequency (MDF), the relative delta, theta and 
alpha activities. Usualty the parameters of the 3 power spectra were avaraged. 
However, one spectrum was sometimes discarded in case of pronounced muscte 
activity in the beta frequency band or asymmetry between the leads T4-02 and T3-01. 
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The MDF was defined as 
(f;=frequency i, S;=power of frequency i, n=the number of frequencies); delta activity 
comprised frequencies 1.0·3.5 c/sec, theta activity that of frequencies 3.5-8.0 c/sec, 
the alpha activity that of frequencies 8.0-13.0 c/sec, and the beta activity that of 
frequencies 13.0-25.6 c/sec. 
RESULTS 
In the control group age-related differences in MDF and the relative powers of delta and 
theta activity could not be shown. 
Subsequently the values of the above mentioned parameters for the control group and 
for the 5 groups of patients with varying degrees of HE were compared. In figure 1 
scatter diagrams illustrate the MDF and the relative powers of the delta and theta 
activities. The MOFs for the controls and the groups with grade 0 and grade 1 HE 
exceeded 6.4 Hz and clearly differed from those found for the groups with grade 2, 3 
and 4 HE ( s 6.6 Hz). Only one MOF value (grade 2 HE) fell in the empirically defined 
normal range. Furthermore, a distinct slowing of the mean dominant frequency was 
observed with increasing grades of HE, but there was a large overlap of individual data 
in adjacent groups. 
• Figure 1: Mean dominant frequency and quantitative measurement of theta and delta activities 
in normal controls and patients with varying degrees of hepatic encephalopathy grouped 
according to clinical assessment. The relative power of the theta activity probably identifies 
those with latent hepatic encephalopathy who were classified as patients with grade 0 HE. The 
power index of the delta activity can be used to identify patients with severe hepatic 
encephalopathy, who may clinically present as grade 2 HE. The quartiles in the figure are given 
to illustrate the trend of slowing activity in higher grades of hepatic encephalopathy. 
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Although the MDFs of grade 0 and 1 HE patients did not differ from those of normal 
controls, the powers of the theta activity of grade 1 HE were clearly higher (>38%) 
than those of the control group (:534%). For patients with clinical grade grade 0 HE, 
the powers of the theta activity ranged from control values to the values found for 
grade 1 patients. In controls and patients with grades 0 and 1 HE the delta activities 
were almost always :535%. The power of the delta activities found for groups 3 and 4 
HE were ~70%, with the exception of one value of 59% for a grade 4 person. 
Individuals with grade 2 HE are characterized by an abnormally low MDF; further 
differentiation based on the powers of the theta/delta activity appears infeasible. Visual 
examination of the power spectra obtained for patients with grades 2, 3 and 4 HE 
revealed that 9 of the 13 spectra of grade 2 HE showed one peak in the theta and one 
peak in delta range. The other four had only a peak in the delta range and thus 
resembled the power spectra of patients with grades 3 and 4 HE (figure 2). The 9 
patients of grade 2 HE with a biphasic power spectrum could be identified by the 
power of the delta activity of less than 70%. 
DISCUSSION 
This study describes an attempt to validate spectral analysis as an objective 
measurement of hepatic encephalopathy for the individual patient. Patients with grade 
1 HE could be distinguished quite easily from the control group by means of their 
increased theta activity. 
The finding of a wide scatter in the data for persons with clinical grade 0 
encephalopathy was to be expected on the basis of the results of other studies. 
Conventional EEGs (8-9). psychometric tests (8) and biochemical monitoring (9) all 
demonstrated latent hepatic encephalopathy in clinically normal cirrhotic patients. If the 
range of the power of theta activity found for patients with grade 1 encephalopathy is 
used as criterion, then 12 of the 34 patients with clinical grade 0 HE could be classified 
as having latent encephalopathy. 
37 
100.0 Power (J . .LV2/Hz) 100.0 Power (JJ.V2/Hz) 
Grade 1 vs 0 Grade 2 vs 0 
t, 
--grade 1 ,, --grade 2 
I' ---grade o I ---grade 0 
' 
' 10.0 ' 10.0 I 
I I 
I I 
' ' 
I 
' I 
' 
' 
' ' I 
' ' 
' 
,, 
' I 
',, ' 
' ' 1.0 ' 1.0 I 
' I 
' .... / 
I 
-
' 
'--,/' .... 
' 
' 
' ' ' 
' 
~ 
' 
" 
' ' 
" 
,, ' 
'J -
0.1 0.1 
0 5 10 15 20 25 0 5 10 15 20 25 
Power (1J.V2/Hz) 
Frequency (Hz) 
Power (!J.V2/Hz) 
Frequency (Hz) 
100.0 100.0 
Grade 3 vs 0 Grade 4 vs 0 
'' 
--grade 3 
' 
--grade 4 
I' ---grade 0 'I ---grade 0 I I 
I I I 
I I ' 10.0 
' 
10.0 
' I 
I I I 
' I 
I I 
' 
I 
' ' 
I 
' ' 
I ' 
' ' ' 
I 
' ' 
I 
' 
' ' ' ,_, 
' 1.0 ' 1.0 
' 
' ' ' ' 
' ~-~"' ........ , ' '-.. .-"', ... -" 
' ' ' 
' 
' 
-' 
' 
,, 
" 0.1 0.1 
0 5 10 15 20 25 0 5 10 15 20 25 
Frequency (Hz) Frequency (Hz) 
Figure 2: Examples of EEG power spectra of different grades of hepatic encephalopathy. 
The power spectra of patients with grade 0 encephalopathy resemble those of the 
controls. 
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The variation in the delta and theta components found for grade 2 HE was also large. 
Here again we face the problem; should we rely upon the clinical grading, and therefore 
conclude that the changes in the EEG really vary so much, or does the wide scatter of 
these measurements suggest clinical misclassification? The difference in MDF between 
the groups with grades 0-1 HE and those with grades 2, 3 and 4 HE suggests that 
clinical differentiation between subtle and severe grades of encephalopathy is reliable. 
Visual examination of the power spectra of clinical grade 2 patients indicated that 4 
patients with only one peak in the delta band had a more severe encephalopathy that 
was comparable to that of patients with grade 3 and 4 encephalopathy. 
The relative high MDF and low power of delta activity of one patient with grade 4 HE 
appeared to be due to superimposition of bilaterally synchronus activity with a 
frequency exceeding 14 c/sec, probably from a subcortical source, upon the slow 
waves of the delta activity. We consider this to be an exception and did not include 
these values when establishing the limits for each group. A reliable distinction between 
grades 3 and 4 HE could not be made with the theta and delta activities in our material, 
which included a relatively small number of patients with these grades of HE. 
PART TWO 
As described in part one, hepatic encephalopathy can be classified into four grades (0, 
1, 2 and 3-4, respectively) using the parameters MDF and the relative theta and delta 
activities of the power spectrum. A distinction between the grades 3 and 4 hepatic 
encephalopathy could not be made. The EEG, however, is quite different for the grades 
3 and 4, especially with regard to the amplitude of slow waves which are larger in 
grade 3 hepatic encephalopathy (1 ). We therefore investigated the contributary value of 
the total power of the EEG as measured by spectral analysis, in the classification of 
hepatic encephalopathy. To prevent clinical misclassification, the EEG grade of hepatic 
encephalopathy was used to group the measurements. 
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MATERIAL AND METHODS 
Sixty eight electroencephalograms with power spectra from 25 patients (median age 50 
years, range 27-70) with acute and chronic liver disease were selected for the study. 
EEG's were classified by an electroneurologist according to Opel on (1 ). In case he could 
not decide between two grades, the EEG was not included in the study. Ten EEG's 
were classified as grade 0 (age range 36·70 years!. ten as grade 1 (32-63 years). 
fourteen as grade 2 (36-68 years), 16 as grade 3 (27-60 years) and 18 as grade 4 (27-
60 years). 
The technique of the EEG registration and quantitative analysis was similar to that 
described in part one of the paragraph. Since the amplitude of waves between the 2 
hemispheres can differ, the power spectra from T4-02 and T3-01 were used 
seperately. Spectra were discarded when the corresponding EEG registration 
demonstrated technical artifacts or pronounced muscle activity. The total power of the 
spectrum was calculated for the range 1-25.6 Hz and defined as 
(f1=frequency i, S,=power of frequency i). 
RESULTS 
Figure 3 illustrates the individual total powers of the spectrum for the different 
encephalopathy grades. An increase in power was demonstrated with increasing 
severity of encephalopathy, with a maximal power for grade 3. EEG's classified as 
grade 4 encephalopathy varied in power from values lower than those for grade 0 to 
values found with grade 2. Powers of grade 3 encephalopathy differed markedly from 
the other grades. Most values (22 from the 27) were greater than 250 pV2 , whereas 
just 2 of the grade 4 and 5 of the grade 2 values fell in that range. 
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Figure 3: Total power of the spectra in 
different grades of hepatic encephalopathy 
grouped according to EEG evaluation. A total 
power ~250 J1V2 seems to identify grade 3 
hepatic encephalopathy. The quartiles are 
given to illustrate the trend of increasing 
power in higher grades of hepatic 
encephalopathy with a maximum at grade 3 
hepatic encephalopathy. 
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Table 1: Proposed criteria for objective grading of hepatic encephalopathy by automated 
EEG analysis. 
power spectrum 
grade of mean dominant 
encephalopathy frequency (c/sec) power (uV2 ) %theta %delta 
0 <:6.4 <35 
1 ~6.4 <:35 
2 <6.4 
3 <6.4 <:250 
4 <6.4 <250 
DISCUSSION 
Hepatic encephalopathy can be quantitated objectively by spectral analysis. As 
discussed in part one the mean dominant frequency could distinguish between the 
grades 0-1 and 2-4, respectively; a high {=::::35%) relative theta activity appears specific 
for grade 1; and for the grades 3-4 encephalopathy a high ( =:::: 70%) percentage delta 
activity was demonstrated. With the introduction of the total power of the spectrum a 
further differentiation between the grades 3 and 4 seems possible. 
Table 1 presents our proposed scheme for grading individual cirrhotic patients; the 
limits are derived from the results of this study. Since the criteria were chosen 
arbitrarily, the values must be tested in other groups of patients with hepatic 
encephalopathy. A more accurate distinction between the different grades may be 
found using statistical methods in larger groups of patients. 
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Chapter 3 
QUANTITATIVE EEG ANALYSIS AND SURVIVAL IN LIVER DISEASE 
The contents of this chapter have been published in: 
Electroencephalography and Clinical Neurophysiology (1985,61 :502-504) under the 
same title with the following authors: C. C. D. van der Rijt, S.W. Schalm. 
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ABSTRACT 
A simple, objective method for measuring hepatic encephalopathy (automated spectral 
analysis of the EEGl was tested for its prognostic value in a group of 60 patients with 
cirrhosis of the liver and in 10 patients with acute hepatic insufficiency. A highly 
significant correlation was found between the grade of hepatic encephalopathy and 
survival. This study further validates the clinical value of objectively grading hepatic 
encephalopathy by spectral analysis. 
INTRODUCTION 
We reported on a simple automated EEG analysis test (spectral analysis) as an objective 
method to measure hepatic encephalopathy (1 ). With this test encephalopathy can be 
classified in 5 grades. The clinical significance of each grade of encephalopathy, 
however, is not fully determined. Accumulating experience suggests that this objective 
method of grading of encephalopathy is useful for monitoring medical therapy. 
Theoretically, the grade of encephalopathy should have a prognostic significance, since 
hepatic coma is an important cause of death in liver cirrhosis (2-4) and acute fulminant 
hepatitis (5). 
In this retrospective study we investigated the relationship between the grade of 
hepatic encephalopathy and life expectancy in order to validate further the clinical value 
of grading hepatic encephalopathy objectively by spectral analysis. 
METHODS 
Automated EEG analysis was performed in 60 patients with histologically confirmed 
cirrhosis of the liver, and in 10 patients with acute hepatic insufficiency. In the cirrhotic 
group 18 patients were under 46 years of age, 26 were between 46 and 65 years, and 
16 patients were over 65 years. In 25 patients the cirrhosis was due to alcohol 
overconsumption, in 8 to viral infection, and in 27 patients the cirrhosis was 
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cryptogenic or of other etiology. The patients with acute hepatic insufficiency were 
younger than the cirrhotic patients: seven were Jess than 46 years of age, two were 
between 46 and 65 years, and one was over 65 years. 
The technique of automated EEG analysis has been described previously by us (1 ). 
Variations in electric potential in the leads T4-02 and T3-01 (temporo-occipital) were 
registered during 3 epochs of 100 sec. For each 100 sec 10 periods of 10 sec were 
used to construct a mean power spectrum by the Fast Fourier Transformation method. 
To define the grade of hepatic encephalopathy the parameters calculated were: the 
mean dominant frequency, MDF, defined as 
(f;::;;;frequency i, S; =power of frequency i, n=the number of frequencies), the relative 
power of the delta band (1.0-3.5 Hz), the relative power of the theta band (3.5-8.0 Hz) 
and the relative power of the alpha band (8.0-13.0 Hz). They were calculated for the 
range 1.0-25.6 Hz. The criteria to define the grade of hepatic encephalopathy are given 
in figure 1. 
Using this scheme, the grade of hepatic coma was determined in the study population. 
In patients in whom spectral analysis was also performed during follow-up, the first 
test was used for this study. 
Subsequently, survival curves for the grades 0, 1 and 2, and 3 and 4 hepatic 
encephalopathy were prepared using a modification of the Kaplan-Meier method (6). 
First the survival for each patient was determined in months. The percentages of 
patients that had survived 0, 1, 2, ... ,36 months were determined in relation to the 
number of patients at risk each month. Surviving less than 15 days corresponded to a 
survival of 0 months. This procedure explains survival less than 100% at month 0. 
To determine the correlation between survival and grade of encephalopathy the log rank 
test (a standard test for comparing survival curves) was used (7). 
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RESULTS 
Figure 2A gives the survival curves for the whole groups of patients with grades 0, 1 
and 2, and 3 and 4 hepatic encephalopathy. The prognosis for patients with grade 3-4 
hepatic encephalopathy was poor, the majority of the patients dying within 2 months. 
Exclusion of patients with acute hepatic encephalopathy, who all died within a month, 
did not change the survival curve for grades 3-4 encephalopathy markedly (figure 28). 
There was a significant correlation (p = 0.001) between survival and the hepatic 
encephalopathy grade in patients with cirrhosis of the liver, when all patients were 
included in the statistical test. In view of the small number of patients with prolonged 
Grading hepatic encephalopathy 
grade MDF(Hz) %9 %.1 
100.0 leadT 4-o 2 0 ~ 6.4 <35 
T 3-o, ~6.4 ~35 
2A < 6.4 9>.,.1 < 70 
2 8 <6.4 e<t:. <70 
I' 3-4 < 6. 4 ~70 
10.0 I\ 
" 
I I 
:I: \ I \ 
N ' I \ 
> \ "' \ 
"- "' \ I \ 
./ 
,: \ 
• \ T4-02 T3-01 ~ Leads 0 \ mean a. 
" 
MDF.[HzJ 1.0 \ 6.73 6.58 6.63 
\ 
.1Act. [%] 21.9 22.0 22.0 
' 
9Act. [%] 
' 
43.9 46.5 45.2 
a Act. [~] 28.9 27.7 28.3 
~ Enceph. 
' grade 1 1 ~ 
0. 1 
0 5 10 15 20 25 
Freq. Hz. 
Figure 1: Example of a report of spectral analysis to determine the grade of hepatic 
encephalopathy. The power spectra of the two symmetrical leads T3-01, T4-02 are shown on 
the left and the calculated measurements of the mean dominant frequency, the relative 
percentage of the powers of the delta, theta and alpha bands respectively on the right. In the 
upper right corner, our system for grading of encephalopathy is provided. 
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follow-up, differences between individual curves could not be tested. Visual inspection 
suggests that life expectancy in grade 1-2 is only somewhat inferior to grade 0, 
whereas the prognosis of patients with grade 3-4 is markedly different with a 1 year 
mortality of 82%. 
DISCUSSION 
Various methods are being advocated to measure hepatic encephalopathy objectively. 
Validation of these test methods, however, is difficult. Clinical experience (and logic) 
suggests that patients with hepatic encephalopathy have a limited life-expectancy, and 
that the higher the encephalopathy grade the poorer the prognosis. We reasoned that 
an objective test for assessment of hepatic encephalopathy, to be clinically useful, 
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Figure 2: A. Survival curves constructed by the Kaplan-Meier method in acute and chronic liver 
disease according to grade of hepatic encephalopathy (---: grade 0 HE; ----: grades 1-2 HE; 
-----grades 3-4 HE). B. Survival of patients with cirrhosis of the liver. A significant relation 
between survival and grade of encephalopathy was present {log rank test, p=0.001). 
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probably should be able to distinguish patients with a poor prognosis from those with a 
more prolonged life expectancy. 
This study provides evidence that measuring the grade of hepatic encephalopathy by 
means of automated EEG analysis has indeed a prognostic value for survival in cirrhosis 
of the liver. Ufer et a!. (8) and Prytz and Sloth (9) published survival curves following 
the first episode of clinical hepatic coma irrespective of the grade. They reported an 
overall 1 month survival rate of 55-60%, and a 1 year survival of 20%. In patients who 
died following a coma episode, the grade of encephalopathy was said to be somewhat 
higher than that in patients who survived. In our study a 1 month survival of 55%, and 
a 1 year survival of 18% is found only for patients with grade 3-4 hepatic 
encephalopathy. It is therefore likely that patients with grade 3-4 hepatic 
encephalopathy according to spectral analysis are those with unequivocal clinical 
hepatic coma. The 1 month survival of 88% and a 1 year survival of 68% in the grades 
1-2 hepatic encephalopathy are more favourable and do not differ markedly from 
cirrhosis without encephalopathy. However, identification of the group of patients with 
mild or subclinical hepatic encephalopathy by a simple and objective test appears very 
worthwhile, since medical treatment of latent hepatic encephalopathy may improve the 
quality of life in an important way. 
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Chapter 4 
QUANTITATIVE EEG ANALYSIS AND EVOKED POTENTIALS 
TO MEASURE HEPATIC ENCEPHALOPATHY 
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The contents of this chapter have been submitted for publication under the same title 
with the following authors: C.C.D. van der Rijt, S.W. Schalm. 
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Methods for the objective measurement of the depth of hepatic encephalopathy are 
important in scientific investigations and for the follow-up of the individual patient with 
liver insufficiency in general practice. Quantitative EEG analysis has been demonstrated 
to correlate with the severity of hepatic encephalopathy (1 ). Furthermore, the grade of 
hepatic encephalopathy as assessed by spectral analysis seems to have a prognostic 
value (2). In recent years new electroneurologic methods, in particular evoked 
potentials, have been investigated for the detection and quantitation of hepatic en-
cephalopathy. Of the evoked potentials several modalities were advocated: flash visual 
evoked potentials (flash VEP'sl (3-6), pattern reversal visual evoked potentials (7-1 0), 
somatosensory {1 0-121 and brainstem auditory evoked potentials {1 01 {SSEP's and 
BAEP's, respectively) and the measurement of the auditory P300 event-related 
potential, an electric counterpart of the reaction time (9, 13). 
With the introduction of these new methods evaluation of their value for clinical 
practice and scientific investigations seems indicated. The pattern reversal and the 
auditory P300 event-related potentials require patient participation and therefore can 
only be used for the detection of subclinical and mild hepatic encephalopathy. Flash 
VEP's {3-4,6), SSEP's {11) and BAEP's {14) have been studied for their correlation with 
the grades 0-4 encephalopathy, since they can be measured in all patients. No 
correlation with the depth of encephalopathy was found for the latencies of brainstem 
evoked potentials (14), whereas latencies of SSEP's (11) and flash VEP's (3-4,6) 
differed significantly between succeeding grades. The objectivity of flash VEP's, 
however, may be questioned, as three reported studies demonstrated different changes 
in wave pattern, especially with respect to peaks disappearing in higher grades of 
hepatic encephalopathy (3-4,6). According to our own experience on the use of flash 
VEP's in severe hepatic encephalopathy, the identification of distinct wave patterns is 
extremely difficult. A considerable inter- and intraindividual variation, indeed, has been 
reported {151. 
The sensitivities of different methods for the detection of latent hepatic encephalopathy 
may be used to compare automated EEG analysis and different modality evoked poten-
tials more directly. As far as we know, no study reported the correct sensitivity of the 
test, defined as the number of patients with abnormal test results in a group of patients 
with latent hepatic encephalopathy already diagnosed by a method considered as the 
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Table 1: Summary on the percentages of patients classified as having latent hepatic 
encephalopathy by various electrophysiologic methods in patients with chronic or 
acute liver disease without mental alterations. 
Method %latent HE 95-percentiles 1 
EEG 21 12-31 
spectral analysis 20 12-29 
flash VEP 36 25-46' 
pattern reversal VEP 10 4-18 
P300 18 9-29 
SSEP 28 17-38 
BAEP 41 21-64 
Patient groups from the studies used in figure 1 were combined with respect to the studied 
electrophysiologic method. 
1: 95-percentiles were calculated using the formula 1 OO[p ±{1.96'/(pq/n) + 1 /2n}J, if the 
product npq (n=tota! number of patients studied; p=proportion of patients with abnormal 
test results; q = 1-p) was greater than 15; otherwise standard curves were used. 
2: p<0.05 with respect to spectral analysis by f-test. 
golden standard, for instance psychometric tests. Only studies reporting on the 
percentage of cases with test results above the upper limit of normal, in groups of 
patients without clinical signs of hepatic encephalopathy are available. Studies on 
electroneurologic methods for patients without overt hepatic encephalopathy were 
selected and the percentage abnormal results was calculated for each test. Standard 
curves were used to determine the 95% confidence intervals. Figure 1 illustrates the 
results. The highest percentages were found for flash visual and somatosensory evoked 
potentials. After combining separate studies, only flash VEP's classified significantly 
more patients as having latent hepatic encephalopathy than spectra! analysis of the 
EEG (table 1 ). However, different studies may include patient groups with different 
severity of the underlying liver disease and therefore different impairment of 
electroneurologic function. Just three studies reported on spectral analysis and evoked 
potentials together in the same patients (5,9, 13); only two reported on the number of 
patients with abnormal test results indicating latent hepatic encephalopathy (5,9). The 
percentage of abnormal scores found by pattern reversal and auditory P300 event-
related evoked potentials was similar to that of spectral analysis (9), whereas a higher 
percentage of patients with latent hepatic encephalopathy was detected by flash VEP's 
(5). 
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It has to be stated that all known electrophysiologic methods are not specific with 
respect to hepatic encephalopathy. I would therefore conclude that there is not yet 
enough evidence to support the use of evoked potentials instead of spectral analysis for 
the monitoring of hepatic encephalopathy. Flash visual evoked potentials may be 
valuable for the detection of latent hepatic encephalopathy but results in more severe 
encephalopathy are contradictory. Studies on somatosensory evoked potentials are 
scarcely available; direct comparison with automated EEG analysis is awaited. 
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Chapter 5 
FLUMAZENil DOES NOT IMPROVE HEPATIC ENCEPHALOPATHY ASSOCIATED WITH 
ACUTE ISCHEMIC LIVER FAilURE IN THE RABBIT 
The contents of this chapter have been published in Metabolic Brain Disease 
(1990;5:131-141) under the same title with the following authors C.C.D. van der Rijt, 
R.J. de Knegt, S.W. Schalm, O.T. Terpstra and K. Mechelse. 
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ABSTRACT 
The effect of flumazenil, a benzodiazepine antagonist, on hepatic encephalopathy was 
studied in rabbits with acute hepatic failure induced by a two-stage liver 
devascularization procedure. The rabbits were randomized for treatment with 5 mg/kg 
of flumazenil or the placebo. The drug was administered at two easily recognizable time 
points in the course of the encephalopathy: firstly when the righting reflex was dis-
turbed, secondly when the animal could no longer achieve to the sitting position. The 
response after flumazenil did not differ from that after the placebo, as measured by 
clinical evaluation and automated EEG analysis. Furthermore, the progression of the 
encephalopathy, as measured by the survival time after the first injection, was not 
affected by flumazenil. 
INTRODUCTION 
Benzodiazepine receptor antagonists have been reported to improve hepatic 
encephalopathy (HE) in experimental (1-4) as well as clinical (5-10) studies. The 
benzodiazepine receptor is part of the larger gamma-aminobutyric acid (GABAJ-
benzodiazepine receptor complex (11 ). lt has been suggested that this receptor system 
may play a role in the pathogenesis of HE {12). Gamma-aminobutyric acid (GABA) is 
the most important inhibitory neurotransmitter, accounting for 30-40% of the total 
neurotransmitter content in the brain (13). The binding of GABA to its receptor, and 
thus its inhibitory action on neuronal membranes, is enhanced by the binding of 
benzodiazepines to their own receptors (11 ). Benzodiazepine antagonists inhibit the 
binding of benzodiazepines but, on their own, are not believed to have an important 
intrinsic effect on central nervous system functioning (11 ). Therefore, apart from 
offering a new therapeutic approach to HE, benzodiazepine antagonists may be 
important in studies on its pathogenesis: a beneficial effect may point to the presence 
of endogenous benzodiazepine-like compounds in HE, as has been recently suggested 
(14). 
Various compounds that antagonize the benzodiazepine receptor have been studied in 
animal models of acute hepatic failure: flumazenil, CGS 8216 and Ro15-4513. All 
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ameliorated hepatic encephalopathy in rats and rabbits with galactosamine or 
thioacetamide-induced fulminant hepatic failure {1-4). However, a beneficial effect of 
CGS 8216 could not be confirmed in rats with acute ischemic liver failure (15). 
Furthermore, antagonism of the GABA-receptor itself also did not affect the course of 
hepatic encephalopathy in this animal model (16). Therefore, further experimental 
controlled studies on the effect of a benzodiazepine antagonist in hepatic 
encephalopathy are needed. We studied the effect of flumazenit in our recently 
described rabbit model of acute ischemic liver failure (17). We measured the response 
by clinical evaluation of HE, spectral analysis of the EEG and determination of the 
survival time. 
MATERIAL AND METHODS 
Animals: Sixteen New Zealand white rabbits with acute ischemic liver failure were 
used. Four healthy control rabbits were studied to assess the intrinsic effect of 
flumazenil in comparison to that of diazepam. 
Rabbits with acute hepatic encephalopathy: Before surgery the rabbits received 
doxycycline, in dosages increasing to a maximum of 25 mg, in their drinking water for 
about 5 days. Food was withdrawn 24 hr before surgery, except for glucose drinking 
water ad li~itum. Anesthesia was induced with Hypnorm (0.6-0.8 m! im; 10 mg of 
f!uanison and 0.2 mg of fentanyl base/ml). After intubation muscle relaxation was 
achieved with 1.0 mg of Pavulon iv, and anesthesia was maintained with N20:0 2 (2:1) 
and 0.025 mg of fentanyl iv, whenever indicated. A Ringer-lactate solution {20 ml/hr) 
and Haemacel (1 0 ml/hr) were administered via a cannula in a marginal ear vein during 
the operation. To prevent acidosis, the infusion regimen was changed to 8.4% sodium 
bicarbonate at a rate of 15 and 30 ml/hr during and immediately after construction of 
the portacaval shunt (PCSL respectively. To monitor arterial blood pressure, blood 
gases and pH, a 5 Ch catheter was inserted in the right femoral artery. Fifty mg of 
amoxici!line were given as antibiotic prophylaxis. 
The surgical procedure was performed as previously described (17). After severing the 
attachments of the liver, a small-diameter {5mm) side-to-side PCS was constructed 
with 7·0 prolene within 15 minutes. A loose ligature was placed around the 
hepatoduodena! ligament and threaded through a subcutaneous plastic tube. Three 
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silver electrodes were placed directly on the duta mater through small burr holes in the 
skulL Two were implanted 5 mm to the right of the sagittal suture, 3 mm anterior and 
11 mm posterior to the coronal suture, respectively, and the third was implanted 5 mm 
to the left of the sagittal suture and 3 mm anterior to the coronal suture. 
Postoperatively the rabbits were given glucose water ad libitum, followed by a normal 
diet. The second day after surgery 50 mg of amoxiciiline was given iv and acute liver 
ischemia was induced by tightening the loose ligature around the hepatoduodenal 
ligament. To prevent hypoglycemia, an infusion of 10% glucose (5 ml/hr) was started, 
the dose being adjusted to maintain normoglycemia, which was controlled hourly. Body 
temperature was measured every 2 hr and remained normal throughout the experiment. 
Before the induction of liver ischemia and at regular intervals in the course of the 
experiment, spectral analysis was performed and arterial blood samples were taken. 
Every half-hour the rabbits were taken out of their restraining boxes for evaluation of 
the stage of HE. Two easily recognizable clinical stages of HE could be identified in 
most animals. Stage A was characterized by a disturbed righting reflex: the animal not 
getting up immediately when placed on its side. At stage B the rabbit lay in the cage 
and could not come to the sitting position, not even after stimulation, and usually did 
not even lift its head. In some cases stage B was preceded by a period of agitation or 
marked ataxia. When stage A or B was identified the evaluation was repeated 10 min 
later for confirmation. 
The rabbits were randomized for treatment with flumazenil or placebo. Flumazenil or 
the vehicle, 5 mg/kg, was injected at a rate of 1 mg/kg/min. The effect of flumazenil on 
HE was evaluated clinically before and 10 minutes after the injection as well as by 
spectra! analysis before and 5 min after the injection and by determination of the 
survival time after the first injection of flumazenil or placebo. Liver failure was 
confirmed by a rise in arterial ammonia levels and a decline in clotting factors. Autopsy 
studies of all rabbits were performed to verify that the hepatoduodenal ligament was 
adequately clamped. 
Control rabbits: Hypnorm, 0.5 ml/kg, was administered intramuscularly and electrodes 
were placed on the dura mater, as described above. The effect of flumazenil was 
assessed in a randomized cross-over study performed at least 1 week after the surgical 
procedure. For this purpose 5 mg/kg of flumazenil or the vehicle was injected at a rate 
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of 1 mg/kg/min. After a wash-out period of one week the other compound was given. 
The effect was assessed by clinical evaluation of the animal before and 1 0 minutes 
after the injection and by spectral analysis before and 5 min after the injection. A 
similar cross-over study was carried out to evaluate the effect of 5 mg/kg of diazepam 
versus that of 0.9% saline. 
Spectral analysis: The variations in potential between the electrodes over the right 
hemisphere were registered by an EEG apparatus (Ahrend-Van Gogh, Amsterdam, The 
Netherlands) and fed into a computer at a sampling rate of 51.2 Hz and a sensitivity of 
11 bits/5V. A power spectrum was established, as described earlier (18). The 
frequency resolution was 0.1 Hz. The mean dominant frequncy (MDF), the power and 
the percentages of the delta, theta, alpha and betha frequency bands were calculated 
over the frequency range 1.0-25.6 Hz. 
Chemicals: Flumazenil was kindly provided by Hoffmann-la Roche & Co, Mijdrecht, The 
Netherlands. Just before the experiment it was suspended in sterile distilled water at 
3rC with Tween 80 (1 drop per 5 ml). Diazepam was solubilized in water with alcohol 
(1 0%) and propylene glycol (40%). Clotting factors were assessed by means of the 
Normotest (Nyegaard, Oslo, Norway). Arterial ammonia levels were measured by an 
enzymatic method using glutamate dehydrogenase. 
Statistics: The Wilcoxon two-sample test was used for statistical comparisons. The 
effects on the MD F and survival times were analyzed with the paired- or non-paired 
Student's t-test, whenever indicated; for analyzing the survival times logarithmic 
transformation was 
used. 
Table 1: Clinical recovery after flumazenil or placebo. 
stage A 
stage B 
Flumazenil 
0/8 
1/6 
Placebo 
0/8 
1/5 
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RESULTS 
Rabbits with hepatic encephalooathy: The degree of liver failure, as measured by the 
rise in arterial ammonia levels and the decline in Normotest values, in the group of 
rabbits treated with flumazeni! was similar to that found for the placebo group (figure 
1 ). 
At stage A the effect of flumazenil or placebo could be studied in all 16 rabbits, 
although the time between the induction of !iver ischemia and the diagnosis of this 
stage of HE varied considerably: 1.5-11.0 hrs for the flumazenil-treated and 1.5-10.5 
hrs for the placebo group. The righting reflex did not normalize in any of the rabbits 
after administration of either flumazenil or the placebo (table 1 ). Two rabbits treated 
with flumazenil and three rabbits receiving the placebo died before stage B was 
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Figure 1: Parameters of acute hepatic failure: on the left, the rise in 
arterial ammonia levels during the first 8 hours after induction of liver 
ischemia; on the right, the hourly decrease in clotting factors, as 
assessed by Normotest. The results are expressed as mean ± SEM. 
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Figure 2: Survival times after the first injection of f!umazeni! or the placebo: on the 
left, absolute values; on the right the same survival times after logarithmic 
transformation to obtain a normal distribution (--=mean). 
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identified or confirmed (most of them were agitated just before death). Therefore, at 
stage B 6 rabbits could be given flumazenil and 5 rabbits the placebo. In each group 1 
animal died within 1 0 minutes of the injection and 1 animal regained the ability to sit 
(table 1 ). 
The survival times after the first injection of either flumazenil or the placebo are shown 
in figure 2. Logarithmic transformation of the data was used to obtain a normal 
distribution. As the mean ratio of the survival times for the two groups after 
administration of the first injection was 1.04 (with a 95%-confidence interval of 0.72 
to 1.49), progression of HE was similar for flumazenil and the placebo. 
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Table 2: Changes in MDF (Hz) after treatment of hepatic encephalopathy with flumazenil or 
placebo. 
stage A 
baseline before 
Flumazenil 5.33±0.40 4.69±0.22' 
(81 (8) 
Placebo 6.00±1.14 5.38±0.77' 
(81 (8) 
a: difference with respect to baseline: p<0.01 
b: difference with respect to baseline: p<0.02 
c: difference with respect to baseline: p<0.05 
after 
4.55±0.90' 
(8) 
4.93 ± 1.06' 
(8) 
stage B 
before after 
4.20±1.20 4.28±2.27 
(6) (5) 
4.92 ± 1.41' 3.60±0.74' 
(51 (4) 
Results are expressed as mean± S.D.; the number of rabbits is given in parentheses. 
Table 3: Changes in the parameters of spectral analysis for control rabbits after treatment 
with f!umazenil or diazepam. 
rabbit MDF power delta theta alpha beta 
(Hz) (%) (%) !%1 (%) (%) 
flumazenil 
1 +0.1 +0.53 -0.3 -1.8 +0.7 + 1.4 
2 +0.5 -43.67 -3.9 +0.5 +0.8 +2.6 
3 +0.4 -20.59 -5.6 +2.7 -1.2 +3.6 
4 +0.5 -13.41 -6.0 +2.0 +2.2 + 1.8 
diazepam 
1 -1.7 +484.62 +25.3 -17.3 -5.8 -2.2 
2 -0.4 + 713.36 + 15.6 -16.5 -2.7 +3.6 
3 -0.5 +612.85 +8.4 -5.7 -4.4 + 1.5 
Results are expressed as the changes with respect to the baseline values after diazepam or 
flumazenil minus these changes after the placebo; the change in power is expressed as the 
percentage change assuming that the power at baseline was 100%. 
The effects of flumazenil and placebo on the MDF's are shown in table 2 and figure 3. 
At stage A the MDF's were already significantly decreased with respect to baseline 
values (paired Student's t-test). At this stage neither flumazenil, nor the placebo 
induced normalization to the baseline values (table 2). At stage 8 t~e MDF's were 
decreased further, except in one animal with an MDF higher than the baseline value; in 
this animal a further increase occurred from 5.9 to 8.1 Hz after flumazenil, due to a 
peak in the power spectrum around 15 Hz. A similar effect did not occur in other 
animals. 
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At both stages of HE the changes in MDF with respect to the values before injection 
were calculated for each rabbit. The changes did not differ between flumazeni! and 
placebo. At stage A the mean difference between f!umazenil and placebo was 0.31 Hz 
with a 95 %-confidence interval of -0.54 to 1.16 Hz. At stage 8 the mean difference 
was 1.07 Hz with a 95%-confidence interval of -0.68 to 2.82 Hz. There were a!so no 
differences in the effects on power and the delta, theta, alpha and beta percentages of 
the power spectrum after the first as well as the second injection. 
Control rabbits: The effects of flumazenil and the placebo were studied in four rabbits 
and the effects of diazepam and physiologic saline in three rabbits. After flumazenil 
behavioral changes did not occur and spectral analysis showed only minimal changes 
(table 3). A similar dose of diazepam induced marked lethargy: the animals could be 
placed on their sides and they slept for the following hour. Electroencephalography 
revealed a high amplitude rhythm with an increase in background delta activity. These 
changes were confirmed by the marked increase in power and % delta activity as 
measured by spectral analysis. The MDF, the % theta and the % alpha activity 
decreased (table 3). 
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Figure 3: Changes in MDF after treatment of hepatic encephalopathy with f!umazenil or 
placebo: on the left, rabbits treated with flumazenil; on the right, rabbits receiving the placebo. 
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DISCUSSION 
We could not demonstrate a beneficial effect of flumazenil on hepatic encephalopathy 
in our animal model of acute hepatic failure. Our findings are in accordance with the 
results from a rat model of acute ischemic liver failure (15). An important role for an 
endogenous benzodiazepine-like compound in this animal model therefore seems 
unlikely. Our findings are contrary to the results of experimental controlled studies on 
benzodiazepine antagonists in galactosamine and thioacetamide-induced acute liver 
failure (1-4). 
In the galactosamine animal models the effect of a benzodiazepine antagonist was 
investigated only during mild hepatic encephalopathy. All rats apparently regained 
normal clinical status (1) and neurological response scores improved in 75-100% of the 
rabbits (2). Disturbed visual evoked responses normalized in both studies (1 ,2). We 
could not demonstrate a clinical effect of flumazenil in any of the rabbits in stage A. 
The upper limit of the 95%-confidence interval for this response in 8 rabbits, 36.9%, is 
therefore still much lower than the responses observed in the galactosamine models 
(1 ,2). Furthermore, the MDF after flumazenil neither normalized to the baseline value 
nor showed an improvement significantly different from that in the animals receiving 
the placebo. Regarding the 95%-confidence intervals for the difference in effect on the 
MDF between flumazenil and placebo (-0.54 to 1.16 Hz at stage A and -0.68 to 2.82 
Hz at stage Bl a small effect of flumazenil cannot be excluded. Nevertheless, a 
discrepancy exists between the results in the galactosamine animal models (1 ,2) and 
the results in our model of acute ischemic liver failure. 
We used a highly reproducible rabbit model in which acute hepatic failure was induced 
by a two-stage liver devascularization procedure. Liver failure was confirmed by a 
decrease in clotting factors and a rise in arterial ammonia levels. All animals developed 
encephalopathy, as confirmed by the occurrence of two easily recognisable features of 
the encephalopathy: a disturbed righting reflex in all and loss of the ability to maintain 
posture. The survival of the animals after induction of liver ischemia was similar to that 
reported after total hepatectomy (19), which confirms the suitability of this animal 
model. Recently, the usefulness of an ischemic animal model for the study of hepatic 
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encephalopathy has been questioned (20); however, scientific evidence is not available 
for this statement. 
The concept of investigating the effect of a benzodiazepine antagonist on hepatic 
encephalopathy originated from studies on galactosamine-induced liver failure in rats 
and rabbits, in which increased numbers of brain GABA and benzodiazepine receptors 
were demonstrated using ligand-membrane binding essays (1 ,21-22). Both flumazenil 
and CGS 8216 were found to have a beneficial effect in these animal models (1 .. 2) and 
antagonism of endogenous benzodiazepine-like compounds was suggested. However, 
later studies on the numbers of GABA and benzodiazepine receptors in different animal 
models of hepatic encephalopathy, including the rat model of acute ischemic liver 
failure, yie!ded no changes in GABA and benzodiazepine receptors (23-28). 
Furthermore, the finding of increased numbers of brain GABA and benzodiazepine 
receptors in the galactosamine rabbit model has recently been retracted (29). 
Nevertheless, increased GABA-ergic tone is still postulated in this animal modet (29). A 
beneficial effect of a benzodiazepine antagonist on hepatic encephalopathy may be 
found only in an animal model in which the influence of the GABA-benzodiazepine 
receptor complex on central nervous system function is enhanced. 
Another consideration seems worthwhile. Flumazenii may not only bind to central 
benzodiazepine receptors. A beneficial effect of flumazenil upon blood pressure 
homeostasis was demonstrated in an animal model of hemorrhagic shock (30). A drop 
in blood pressure has been reported in galactosamine-induced liver failure (31,32) and 
may have contributed to the encephalopathy in this animal model of acute hepatic 
failure. 
Differences in the types and doses of benzodiazepine antagonists might also explain the 
discordance between different studies. In the only published study on rabbits (with 
galactosamine-induced tiver failure) a dose of 1-2.5 mg/kg of f!umazenil was used to 
ameliorate hepatic encephalopathy (2). We used a higher dose: 5 mg/kg. This dose has 
been proven to antagonize marked benzodiazepine-induced slowing of the EEG in 
healthy rabbits, without causing any changes when given alone (33). To confirm the 
absence of an intrinsic benzodiazepine-like effect of flumazenil when given at this rather 
high dose, we compared the effects of a dose of 5 mg/kg of flumazenit and diazepam in 
healthy rabbits. Contrary to diazepam, flumazenil induced neither behavioral changes 
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nor slowing of the electroencephalogram. Therefore, our negative findings cannot be 
explained easily by dose differences. 
We studied the effect of flumazenil in both early and late hepatic encephalopathy. Since 
no effect of f!umazenil could be detected in stage A, which occurred early in the course 
of the experiment, when brain edema was almost certainly absent, our negative 
findings cannot easily be explained by the presence of brain edema. 
Fiumazenil has been suggested to be of benefit in the treatment of hepatic 
encephalopathy in some uncontrolled clinical studies (5-10). However, negative results 
have now also been forthcoming (34-36). Furthermore, GABA and benzodiazepine 
receptors were found to be unchanged in autopsied brain tissue from cirrhotic patients 
with hepatic encephalopathy (37). At present, no unequivocal evidence for an increased 
GABA-ergic tone is present in human hepatic encephalopathy. Our negative findings on 
the effect of flumazenil in our animal model of hepatic encephalopathy warrant further 
caution for its postulated benefit in clinical hepatic encephalopathy. 
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Chapter 6 
FlUMAZENil THERAPY FOR HEPATIC ENCEPHALOPATHY: 
A DOUBLE-BLIND CROSS-OVER STUDY 
The contents of this chapter have been submitted for publication under the same title 
with the following authors: C. C. D. van der Rijt, S.W. Schalm, J. Meulstee, Th. Stijnen. 
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ABSTRACT 
The effect of flumazenit a benzodiazepine antagonist, on hepatic encephalopathy was 
investigated in a double-blind cross-over study. The eighteen patients who participated 
in the study had undergone conventional therapy for at least 24 hours; pre-study 
screening did not reveal neurological or non-hepatic metabolic disorders that could have 
induced encephalopathy. The first 9 patients were studied for two 3-day periods , 
separated by one wash-out day. In each period a single injection (1.0 mg) of flumazenil 
or the placebo was followed by a continuous infusion of 0.25 mg/hr for three days. The 
effect was studied by means of clinical evaluation, EEG grading and quantitative EEG 
analysis before and 15 minutes after the single injection and at 24, 48 and 72 hours. 
The last 9 patients were only studied for 2 days to determine the immediate effects of 
flumazenil and the placebo given in randomized order on 2 consecutive days. Cross-
over analysis could be performed in 16 cases for the study of the immediate effect and 
in 8 cases for the study of the steady-state effect. There was a trend toward a 
decrease in the clinical grade of hepatic encephalopathy 15 minutes after bolus 
injection of flumazenil (p=0.06). However, neither EEG grading nor quantitative EEG 
analysis changed significantly. Furthermore, the effect of flumazenil on the clinical 
grade, the EEG grade and spectral analysis was not significantly different from that of 
the placebo during the 3 days of infusion. In a separate open study 13 patients, who 
were excluded from the double-blind study largly because of renal failure or evidence of 
recent use of benzodiazepines, underwent evaluation to determine the immediate effect 
of 1.0 mg of flumazenil. The mean dominant frequency increased significantly in this 
group of patients; an effect on the clinical and/or EEG grades of encephalopathy was 
found only for patients who had previously received benzodiazepines. Our study does 
not support a therapeutic effect of flumazenil on hepatic encephalopathy itself; a 
beneficial effect may however occur when benzodiazepines contribute to the 
encephalopathy. 
INTRODUCTION 
Flumazenil is the first benzodiazepine antagonist to be used in clinical practice. Its use 
has also been suggested for the treatment of hepatic encephalopathy since the 
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publication of several uncontrolled clinical studies on the effect of flumazenil in acute as 
well as chronic liver failure (1-7). In the two largest studies, response rates of 60 and 
71% were reported (1-2). 
Studies on flumazenil therapy for hepatic encephalopathy arose from the idea that 
altered GABA-ergic neurotransmission is of prime importance in the pathogenesis of 
hepatic encephalopathy (8). After controversial findings on the number of GABA and 
benzodiazepine receptors (9-19), GABA metabolism (17,20-24) and brain GABA 
concentrations (17 ,22), interest focussed on the role of a putative endogenous 
benzodiazepine agonist in liver disease {25). Not only did experimental studies support 
the presence of benzodiazepine-like agents in the brains of animals with acute hepatic 
failure (26-23), but such agents were also reported to be isolated from serum and CSF 
from patients with hepatic encephalopathy (25,29-30). Benzodiazepine agonists 
enhance the binding of GABA to its receptor and thus the inhibitory effect of GABA on 
central nervous system functioning. Benzodiazepine antagonists, such as flumazeni!, 
inhibit this effect of benzodiazepine agonists (31 ). Therefore, if benzodiazepine agonists 
play an important role in the pathogenesis of hepatic encephalopathy flumazenil should 
ameliorate hepatic coma. 
However, although quite remarkable success rates were found in uncontrolled clinical 
studies, the lack of an effect of flumazenil on hepatic encephalopathy has also been 
reported (32-33). Controversial results were also obtained in animal experiments: 
beneficial effects of a benzodiazepine antagonist in galactosamine and thioacetamide-
induced hepatitis {34-361 and negative findings for ischemic liver failure (37-38). 
Therefore, controlled clinical trials were considered necessary. 
We studied the effect of flumazeni! on hepatic encephalopathy in patients with acute 
hepatitis and chronic liver disease, using a double-blind cross-over design. We 
measured the response by means of quantitative EEG analysis, an objective assessment 
of brain dysfunction in liver disease (39). 
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PATIENTS AND METHODS 
Before the start of the study the protocol was reviewed and accepted by the Medical 
Ethics Committee of our hospital. Informed consent was obtained from patients with 
low grades of hepatic encephalopathy before the start of the study and from patients 
with severe encephalopathy during the study when the encephalopathy became less 
severe. 
Patients: 
Between February 1987 and February 1990, 54 patients with histologically confirmed 
acute or chronic liver disease were screened for eligibility for our study on the effect of 
flumazenil on hepatic encephalopathy. Only patients with an elevated arterial blood 
ammonia level (>30 umol!l) and encephalopathy diagnosed objectively by spectral 
analysis (39) after at least 24 hours of standard therapy were included. Standard 
therapy consisted of protein restriction and bowel cleansing (lactul ose with or without 
neomycin). Exclusion criteria were: structural neurological disorders of possible 
importance as far as the encephalopathy was concerned found by careful neurological 
examination and, when indicated, CT-scanning; intoxication; marked abnormalities in 
blood biochemistry other than parameters of liver function (glucose, electrolytes, urea 
and arterial blood gas analysis); previously diagnosed endocrinological disease that 
could have induced encephalopathy; hypersensitivity to benzodiazepines; and (recent) 
use of benzodiazepines. HPCL plasma analysis for benzodiazepines was performed 
~~>legend to table 1 : 
1. underlying liver disease: C cirrhosis; c· acute exacerbation of cirrhosis; F fibrosis; H 
hepatitis; HCC hepatocellular carcinoma 
2. etiology of the underlying liver disease; AFLP acute fatty liver of pregnancy 
3. clinical grade and EEG grade of encephalopathy before treatment 
4. Glasgow Coma Scale, calculated from the sum of the eye response (1 =no response; 
2=open in response to pain; 3=open in reaction to verbal command; 4=open without 
stimulus), the motor response (1 =no response; 2=extension in response to pain; 3=flexion 
in response to pain; 4=appropriate motor response to pain; 5 =execution of commands) and 
the verbal response (1 =no response, 2=grunting in response to pain; 3=incomprehensible 
speech; 4=comprehensible speech); t=score of motor and eye response only because of 
intubation of the patient. 
5. evidence for recent use of benzodiazepines as obtained from history and by HPLC plasma 
analysis. Cl chlordiazepoxide; D diazepam; M midazolam; 0 oxazepam; L lorazepam; # 
impossible because of technical artefacts; midazolam could not be detected by HPLC; ? small 
peak in the HPLC spectrum which could not be identified with certainty. 
Table 1: Initial features of patients included in the study. 
liver disease encephalopathy benzodiazepines5 
nr sex age type' etiology2 duration clin.gr EEG gr3 GCS4 history plasma comments 
double-blind study 
1 F 55 H unknown 6 day 0 2 13 
2 F 22 H AFLP1 1 day 1 2 13 
3 F 49 c' nonA·nonB 3 days 1 3 13 I deteriorating renal function 
4 F 61 c PBC 3 months 1 2 13 
5 F 65 c unknown 13 years 1 2 13 porto-systemic shunt (PSS) 
6 F 18 H auto-immune 3 days 1 2 13 0 
7 M 38 c hepatitis B 6 days 2 2 13 partial hepatectomy after HCC 
8 F 61 c unknown 1 year 3 3 9 urinary infection; hypothyroidism 
9 M 46 C' alcohol 12 days 3 4 12 died on the last day of the study 
10 M 53 c alcohol 1 month 2 4 13 urinary infection; spinal tuberculous abces 
11 M 59 c alcohol 5 months 1 2 13 
12 F 23 H hepatitis B 1 day 4 3 6 
13 M 62 c unknown 6 weeks 1 2 13 
14 M 55 c alcohol 7 days 1 1 13 
15 F 63 c PBC 5 weeks 1 2 13 
16 F 42 H toxic 1 day 4 3 9 
17 F 55 c PBC 1 month 1 2 13 
18 M 67 c alcohol 14 months 1 2 13 
opon study 
1 F 17 H toxic 5 days 4 4 2' respiratory infection 
2 M 65 c alcohol 14 days 2 2 13 D retroperitoneal abces 
3 M 18 H unknown 2 days 4 4 6 D # 
4 M 63 c unknown 2 days 4 3 9 I renal failure 
5 F 54 F congenital 1 day 1 2 13 PSS; no protein restriction 
6 M 33 c alcohol 8 days 4 2 8 Cl Cl renal failure; urinary infection 
7 M 65 c alcohol 26 days 4 4 5 D renal failure; urinary infection 
hepatitis B 
8 F 69 c· unknown 4 days 1 2 13 renal failure; obstipation 
9 F 46 H hepatitis B 4 days 3 3 6' D,M 
10 M 40 C/HCC hepatitis B 10 days 3 13 renal failure 
11 M 61 c hepatitis B 11 days 2 3 13 renal failure 
12 F 34 c alcohol 13 days 1 2 13 Cl Cl 
13 F 33 c alcohol 2 days 4 3 4 L carbamezapine for epilepsy 
14 M 48 H unknown 6 days 2 3 11 N renal failure .... .... 
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before acceptance into the study. 
Eighteen patients were considered eligible for the double-blind cross-over study. The 
characteristics of these patients are given in the tables 1 and 2. Two patients (cases 6 
and 12) were withdrawn after the first study day because of liver transplantation, 
leaving 1 6 patients for the final cross-over analysis. HPLC plasma analysis failed to 
show unequivocal evidence for the use of benzodiazepines by these patients. 
Table 3 summarizes the reasons for exclusion of the other patients. Fourteen of the 
excluded patients participated in the open study (tables 1 ,2). 
Table 2: Laboratory data for groups before initiation of the study. 
study I ln~181 study II In~ 14) 
mean SD mean SD 
Hb lmmol/11 7.2 1.2 7.2 1.6 
WBC l10'n) 8.8 6.2 16.3 12.6 
platelets (1 0 9 /IJ 133 101 160 95 
antithrombin3 (%) 0.27 0.16 0.24 0.15 
urea (mmol!l) 6.4 6.1 17.8 16.7 
creatinine (pmol/1) 111 57 274 250 
Na (mmol/1) 136 7 137 8 
K (mmol/1) 3.9 0.5 4.2 0.6 
Ca (mmoi!IJ 2.37 0.15 2.33 0.17 
PD4 lmmol/11 0.80 0.37 1.32 0.72 
protein (g/[) 64 12 62 11 
albumin (g/1) 27 5 25 5 
bilirubin (pmol/l) 244 228 333 228 
alk. phosph. IU/11 183 141 156 53 
ASAT IU/11 188 271 138 103 
ammonia (pmol!ll 113 40 110 49 
Treatment and evaluation: 
Double-blind cross-over study: From the start of the study in February 1987 until 
November 1988 the first 9 patients were studied for two 3-day periods separated by 
one day to minimize carry-over effects. The order in which flumazenil and the placebo 
were administered was randomized. ln each period a first dose of 1 .0 mg of flumazenil 
in 10 ml of vehicle or 10 ml of the vehicle alone was given intravenously (0.1 mg/min.) 
to study the immediate effect. Four hours later a loading dose of 0.5 mg was followed 
immediately by a continuous infusion of 0.25 mg/hr for three days to study the 
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Table 3. Reasons for exclusion from the double-blind trial. 
total number excluded: 36 
reason number 
history of hypersensitivity to benzodiazepines 1 
previous or current use of benzodiazepine 1 5 
use of non-benzodiazepine sedatives 2 
renal faiture 14 
severe hyponatremia 1 
hypoxia 4 
neurological abnormalities 5 
possible Korsakoff's syndrome 2 
incomplete standard therapy 3 
no patient consent 2 
transplantation 3 
potential long-term effect. Standard therapy was continued during the study period. 
The depth of encephalopathy was assessed by clinical grading, conventional EEG 
grading and spectral EEG analysis before and 1 5 minutes after the first injection. The 
same 3 features were assessed 24, 48 and 72 hours after the start of each of the two 
study periods, and the average values of these measurements at 24, 48 and 72 hours 
were calculated. 
From November 1988 until February 1990, the cross-over study was simplified by 
focusing on the immediate effect of f!umazeni!. One dose of flumazenil (1 mg/1 Oml) and 
one dose of the placebo (1 Oml) were given on two consecutive days. The depth of 
encephalopathy was assessed before and 15 minutes after injection. 
Open study: Fourteen patients excluded from the controlled study participated in an 
open study. One mg of flumazeni! was injected at a rate of 0.1 mg/min. Clinical 
evaluation, EEG grading and spectral analysis were performed before and 15 minutes 
after injection. 
Assessment of heoatic enceohalopathy 
Clinical grading. Grade 0 hepatic encephalopathy was defined as the absence of at least 
3 of the following abnormalities: inverted sleep pattern, disturbed memory, impaired 
calculation (serial 7's) and slowness of speech; grade 1 as the presence of at least two 
of these abnormalities (one abnormality in association with a flapping tremor was also 
classified as grade 1 ); grade 2 as the presence of at least 2 of the following: lethargy, 
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disorientation in time and flapping tremor; grade 3 as the presence of at least two of 
the following: a state in which the subject must be stimulated repetitively to open his 
eyes or execute commands, disorientation in terms of place and disorientation with 
respect to person; and grade 4 as coma. 
EEG grading. Grade 0 hepatic encephalopathy was defined as the presence of a 
background activity consisting of alpha rhythm; grade 1 as an alpha rhythm with some 
scattered theta waves; grade 2 as a background activity of theta rhythm intermixed 
with some delta and alpha frequencies; grade 3 as a background of polymorphic delta 
activity of high amplitude with spontaneous variability; and grade 4 as delta activity of 
relatively small amplitude (40). 
Spectral analysis. Automated EEG analysis was performed, as described earlier (39). 
Variations in electric potential in the leads T3-01 and T4-02 (temporo-occipital) were 
registered for 1 00 seconds. Using Fast Fourier analysis a power spectrum was 
constructed from which the mean dominant frequency (MDF) was calculated for the 
range 1.0-25.6 Hz. to measure the response to treatment with flumazenil or placebo. 
HPLC plasma analvsis 
An HPLC system was used to detect benzodiazepines in plasma by means of a 
Chromspher C8 column and a detector with a 254 nm filter. Two analyses were 
performed with eluents consisting of H20, methanol and triethylamine (450:550:5), 
acidified to pH 6.6 with 30% acetic acid and H20, methanol, acetonitrile and 
triethylamine (600:200:200:5), pH 5, respectively. Only peaks characteristic of known 
benzodiazepines were considered evidence for recent use of benzodiazepines. 
Statistical analysis 
Statistical analysis for assessment of the effect of flumazenil in the double-blind cross-
over study was performed according to Armitage eta!. (41 ). The effect of flumazenil on 
the clinical and EEG grades of encephalopathy was tested by the two-sample Wilcoxon 
rank test, the effect on the MDF by the Student's t-test. Differences between the 2 
study periods with respect to laboratory data were evaluated by the paired Student's t-
test. In the open study the paired Student's t-test was used to test the effect of 
flumazenil on the MDF. 
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RESULTS 
Double-blind cross-over study 
The results of assessment of hepatic encephalopathy before and 15 minutes after 
injection of 1.0 mg of flumazenil or the placebo are shown in figure 1. Sixteen patients 
received flumazenil as well as the placebo; two patients could be studied for just one 
day (one received flumazenil and one the placebo). In most cases the hepatic en-
cephalopathy was generally mi!d clinically but electroencephalography revealed marked 
slowing, i.e. grades 2-4 hepatic encephalopathy, in all subjects. Clinical assessment as 
well as EEG grades of hepatic encephalopathy were somewhat higher for the group of 
patients who received the placebo in the first and flumazenil in the second period than 
for those who were treated in the reverse order. 
A period effect over the 2 study periods could not be demonstrated for either the 
clinical grade of HE or the mean dominant frequency, but the EEG grade of HE exhibited 
a significant reduction in severity over the 2 periods (p=0.02). Biochemica!ty, there 
was a trend toward lower ammonia levels in the second period but the decrease was 
not significant (table 4). A significant interaction between period and effect could not 
be demonstrated for either the EEG grade or the clinical grade and MDF. Cross-over 
analysis of the data was therefore justified. 
Fifteen minutes after injection of flumazenil the clinical grade of HE had decreased in 6 
patients; after the placebo a decrease was found in 2 cases and a rise in clinical grade 
in 2 others (p =0.0-6). However, EEG readings did not reveal any changes in the grade 
Table 4: Laboratory data of the double-blind cross-over study. 
period 1 (n ~16) period 2 (n = 1 6) 
mean s.d. mean s.d. p 
Na 134 7.3 135 7.2 0.66 
Ca 2.05 0.14 2.14 0.23 0.09 
P04 0.82 0.34 1.03 0.28 0.01 
urea 7.1 6.2 8.1 8.1 0.20 
ammonia 103 40 89 34 0.06 
PH 7.48 0.05 7.45 0.03 0.07 
P02 11.7 2.8 12.0 3.2 0.81 
PC02 3.8 0.6 3.9 0.6 0.62 
glucose 8.3 5.3 8.5 4.9 0.81 
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of encephalopathy 15 minutes after the injection of either flumazenil or the placebo. 
Furthermore, there were no differences in the changes in MDF with respect to baseline 
values between flumazenil and placebo (p=0.21, 95% confidence interval of -0.42 up 
to 0.68 Hz). Three of the 6 patients with a possibly lower clinical grade of HE 15 
minutes after a single injection of flumazenil belonged to the first group of 9 patients 
who were studied for a longer period. None of these three patients showed clinical 
deterioration four hours after the first injection of flumazenil. Furthermore, a beneficial 
effect of the benzodiazepine antagonist also could not be demonstrated during the 3-
day infusion periods in 8 patients. There were no differences in effect on either the 
clinical and EEG grades of encephalopathy or the MDF's between flumazenil and 
placebo (p>0.05) (fig. 2). The mean difference in the changes in MDF with respect to 
CLINICAL GRADE EEGGRADE MDF (Hz) 
period 1 period 2 period 1 period 2 period 1 period 2 
ftumazenil placebo flumazenil placebo flumazenil placebo 
4 4 8 I 
I ~~ 3 3 6 
2 ~ 2 "'"Wb~-- t 4 =---=------+ 2 0 0 0 
placebo I flumazenil placebo flumazenil placebo flumazenil 
4 I 4 8 ~~ 3 3 6 
2 2 4 
~ : ~ 2 0 0 0 
0 0.25 0 0.25 0 0.25 0 0.25 0 0.25 0 0.25 
time in hours 
Rgure 1: Assessment of each case of hepatic encephalopathy before and 1 5 min after the 
single injection of flumazenil or the placebo during the double-blind study: on the left, the 
clinical grade; in the middle, the EEG grade; on the right, the mean dominant frequency (MOF); 
top panel, subjects who received flumazenii in the first period; bottom panel, subjects who 
received the placebo in the first period. 
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baseline values induced by the infusions of flumazenil and placebo was -0.44 Hz with 8 
95%-confidence interval of -2.22 up to 1.34 Hz. 
Open study 
Hepatic encephalopathy was more severe in these patients than in the subjects of the 
double-blind study {figure 3). Three patients improved clinically after injection of 
flumazenil: 1 subject went from grade 4 to 2 and two from grade 3 to 2 HE. In contrast 
to the results of the contro!ted study, the EEG grade also improved in 2 cases. Further-
more, the MDF increased significantly (p :::;Q.02) with a 95% confidence interval of 
0.29 up to 1.31 Hz. Of the 4 patients who were also given the placebo, 1 subject 
improved clinically from grade 3 to 2. A!! patients who exhibited a change in the ctinical 
and/or EEG grade had previously been treated with benzodiazepines. 
CUN!CAL GRADE 
period 1 period 2 
flumazenil placebo 
EEGGRADE 
period 1 
flumazenil 
period 2 
placebo 
MDF(Hz) 
period 1 period 2 
j~? 
~ 4 3 2 
4 
3 
2 
0 
placebo 
:j& 
2 I 
o I 
flumazenil placebo I flumazenil 
0 \~ 
0 4 24--72 0 4 24--72 0 4 24--72 0 4 24-72 0 4 24--72 0 4 24-72 
time in hours 
Figure 2: Assessment of each case of hepatic encephalopathy before and during the continuous 
infusion of ftumazenil and the placebo during the double-blind cross-over study: on the left, the 
clinical grade; in the midd!e, the EEG grade; on the right, the mean dominant frequency (MDF); 
top panel, subjects who received flumazenil in the first period; bottom panel, subjects who 
received the placebo in the first period. 
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CLINICAL GRADE EEGGRAOE MDF (Hz) 
4 8 ~ 4 ~ ~ 3 3 6 ~ 2 2 4 
2 
0 0 0 
0 0.25 0 0.25 0 0.25 
time in hours 
Figure 3: Assessment of each case of encephalopathy during the open 
study before and 15 minutes after administration of 1 mg of flumazenil: 
on the left, the clinical grade of encephalopathy; in the middle, the EEG 
grade of encephalopathy; on the right, the mean dominant frequency 
IMDFI. 
DISCUSSION 
The findings of our controlled double-blind study do not support a major effect of the 
benzodiazepine receptor antagonist flumazenil on hepatic encephalopathy. Although the 
clinical grade of HE decreased in 6 patients 15 minutes after the injection of flumazenil, 
the effect did not reach statistical significance. Furthermore, the effect was still present 
4 hours after the injection in the 3 patients who were studied for a longer period. Since 
flumazenil is rapidly eliminated from the body and the duration of action is much 
shorter than four hours, even in liver disease (42), the absence of subsequent 
deterioration does not support a dose-effect relationship. Evaluation of the clinical 
grades of HE during the 3-day infusion periods also did not indicate an effect of 
flumazeni!. The same applies for quantitative EEG analysis and conventional EEG 
readings. These results are in accordance with those of animal studies on acute 
ischemic liver failure (37,38). However, they contradict the findings of uncontrolled 
clinical studies that demonstrated a remarkable effect of flumazenil on hepatic 
encephalopathy (1-7). Interestingly, in our open study we also found a significant effect 
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of flumazenil, as measured by quantitative EEG analysis. These patients had been 
excluded from the controlled trial, partly because of recent use of benzodiazepines. 
Controlled studies of hepatic encephalopathy are hampered by the variety of metabolic 
disorders encountered in acute hepatic failure as well as cirrhosis of the liver, renal 
failure being the most common (43). Some metabolic factors, especially uremia, may 
lead to hepatic encephalopathy but can also induce encephalopathy in the absence of 
liver disease. In addition to metabolic complications, the recent use of benzodiazepines 
often also leads to (hepatic) encephalopathy (44). The causes of encephalopathy in liver 
disease are therefore widely varied, and strict selection criteria are needed for 
controlled clinical trials. Of the 54 patients evaluated, only 18 were found to be eligible 
for the study. Similar figures have been reported by others (45). 
Because of the difficulty in randomizing sufficient patients for a clinical trial on hepatic 
encephalopathy, we decided to use a cross-over design for the double-blind study. The 
main problems of such a design are differences in the assessments between the two 
periods due to time and/or carry-over effects (41 ). In our study we could not find a 
period effect for the clinical grade and the MOF, but the EEG grade of HE was 
significantly lower in the second period. In theory, an important carry-over effect must 
have been absent since the elimination half-time for flumazenil in liver disease has 
recently been reported to be 2.0-6.6 hr (42); a wash-out period of 24 hrs should 
therefore be enough to prevent carry-over. We could not demonstrate an interaction 
between the drug effect and the period. Statistical analysis using the results from both 
periods of the cross-over study was therefore justified (41 ). 
The controlled double-blind study consisted of patients with cirrhosis or hepatitis and 
generally mild hepatic encephalopathy. The findings for this group contradict the results 
of several uncontrolled studies (1-7). A response rate of 60-71% was found for the 
two largest series (4-5). In the uncontrolled studies the effect of flumazenil was 
assessed by clinical observation and electroneurology (EEG or evoked response 
examinations). The dose associated with immediate amelioration of hepatic 
encephalopathy was 0.2-1.0 mg in most studies (1-4, 6-7). This dose is the same as 
that used to reverse benzodiazepine-induced sedation after anesthesia or intoxication 
(46). We administered a dose of 1 .0 mg to study the immediate effect of f!umazenil. 
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The continuous infusion of flumazenil gave plasma levels between 10 and 20 ng/1 (Dr. 
H. Drost, Utrecht), the concentration range recommended for antagonism of 
benzodiazepines (47). Grimm el al. (5) used a dose of 2-15 mg/15 min-3 hrs; the onset 
of clinical improvement occurred in 5 out of the 12 cases after administration of 0.3-
1.1 mg. Our negative results cannot therefore be explained by simple dose differences. 
Screening for recent use of benzodiazepines is important to distinguish between an 
effect of flumazenil on hepatic encephalopathy itself and antagonism of 
benzodiazepines taken previously. Plasma analysis for the presence of benzodiazepines 
together with a carefully taken history and study of medical reports is essentiaL Some 
of the improvement in hepatic encephalopathy reported after injection of flumazenil 
(2,33) may therefore be attributable to the use of insensitive methods for detection of 
benzodiazepines. The results of our open study indeed suggest that an effect of 
flumazenil may occur only when benzodiazepine-induced sedation contributes to the 
encephalopathy. However, "endogenous" benzodiazepines, possibly diazepam and 
desmethyldiazepam, have recently been reported to be found in plasma and brain 
extracts from patients and animals with and without hepatic encephalopathy (29,48-
49). The question arises whether screening for benzodiazepines by plasma analysis 
before the start of the study actually excluded all possible responders. We excluded 15 
patients from the primary study because of recent or current use of benzodiazepines. 
Twelve of them were immediately identified by history and the study of medical 
reports; plasma analysis for benzodiazepines was the sole reason for exclusion in only 
one case (nr. 2 in the open study). Small peaks in the plasma HPLC spectrum that 
could not be identified with certainty were found for 5 patients included in the double-
blind cross-over study. Therefore, our negative findings cannot be explained simply by 
' 
a selection bias. 
We studied a selected group of patients with predominantly mild hepatic 
encephalopathy for which standard therapy had been unsuccessful. Extrapolation of our 
results to patients with hepatic encephalopathy in general is therefore not justifiable. In 
our study the number of patients with alcoholic liver disease was limited. According to 
reported effects of alcohol _ on the GABA-benzodiazepine receptor system (50), 
alcoholism may affect the response to flumazenil. In several of the open studies the 
percentage of patients with alcoholic liver disease was higher than in our study (2,4). 
87 
In conclusion we could not demonstrate a dinically important effect of f/umazenil on 
hepatic encephalopathy in a small double-blind cross-over study of a high!y selected 
patient population. Flumazenil may be effective against hepatic encephalopathy induced 
by benzodiazepines. More, and preferably larger, controlled studies of different groups 
of patients are needed to reach a consensus about the effectiveness of flumazeni! in 
hepatic encepa!opathy. 
This study was supported by Hoffmann-La Roche B.V., Mijdrecht, The Netherlands 
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Chapter 7 
PHARMACOKINETICS OF FLUMAZENIL IN LIVER DISEASE 
The contents of this chapter have been accepted for publication in the European 
Journal of Clinical Pharmacology under the title "Pharmacokinetics of flumazenil in 
fulminant hepatic failure" with the foHowing authors: C.C.D. van der Rijt, R.H. Drost, 
S.W. Schalm, M. Schramel. 
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ABSTRACT 
We studied the pharmacokinetics of fiumazenil, a benzodiazepine antagonist, in 4 
healthy volunteers, 3 patients with acute hepatitis and 3 with liver cirrhosis. One and 
2.0 mg of flumazenil were administered intravenously to patients with liver disease and 
control subjects, respectively. Mean residence times and elimination half-Jives in liver 
disease (3.0-9.4 hr and 2.0-6.6 hr, respectively) were 2-6 times the values found for 
volunteers (1.0-1.5 hr and 0.85-1.2 hr, respectively); the plasma clearance rates were 
decreased 3-5 times from 700-850 ml!min for controls to 120-320 ml/min in liver 
disease. 
INTRODUCTION 
Flumazenil, the first benzodiazepine antagonist in clinical practice, is recommended for 
selective reversal of benzodiazepine-induced sedation in anesthesia, intensive care 
patients and cases of intoxication (1 ). increased sensitivity to benzodiazepines has been 
demonstrated in liver disease (2-3); moreover use of benzodiazepines can precipitate 
hepatic encephalopathy (4). Flumazenil may therefore be particularly important as an 
antagonist of benzodiazepines for patients with liver disease. Furthermore, flumazenii is 
under investigation for the treatment of hepatic encephalopathy itself (5-7). 
In healthy volunteers flumazenil is rapidly eliminated from the body by the liver (8-11 ). 
Therefore, it is reasonable to assume impaired elimination in liver disease. We studied 
the pharmacokinetics of flumazenil in healthy volunteers and patients with severe liver 
disease. 
SUBJECTS AND METHODS 
Subjects: Six patients with decompensated severe liver disease participated in the 
study: 3 with acute hepatitis and 3 with liver cirrhosis, as confirmed by biopsy. Patient 
characteristics and markers of the severity of the underlying liver disease are given in 
table 1. The etiology of the liver disease was toxic in case A, auto-immune in C, 
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primary binary cirrhosis in D, hepatitis B in F and unknown in cases 8 and E. The 
patients were treated with the following medications: ranitidine (A,B .. D), prednisone (D), 
diuretics (furosemide and amiloride for D; spironolacton for E) and folic acid (C). Four 
healthy volunteers without a history of liver disease were also studied (subjects G-J). 
They did not use any medication except oral contraceptives (subject I) and showed no 
signs of alcohol abuse. Patients with liver disease received a 1.0 mg dose of flumazenil, 
which was injected over a 10 min period. Blood samples were taken from the 
contralateral arm before injection and 0, 2, 5, 10, 20, 30, 60, 120, 180 and 240 min 
after administration. The healthy volunteers received a higher dose of 2.0 mg of 
flumazenil within 5 min. This higher dose was used to ensure that the plasma 
concentrations of flumazenil in these healthy subjects would exceed the detection limit 
of the assay for the first 3 hours after injection. Blood samples were collected before 
injection and 0, 2, 5, 10, 20, 30, 45, 60, 120 and 180 min after administration. 
Assay method: 
Sample preparation: Bond Elut C18 disposable reversed phase columns (Betron, 
Rotterdam, The Netherlands) were pre-washed with 2.0 ml of methanol, 2.0 ml distilled 
water and 2.0 ml of Sorensen buffer (pH 7 .4). After transfer of 500 pi of plasma and 
1 00 pi of internal standard (50 ng of Ro 15-3505) they were washed twice with 1.0 ml 
of distilled water. Flumazenil was eluted with 0.5 ml of methanol. The eluate was 
evaporated under a stream of nitrogen at 40°C and the residue was dissolved in a 
mixtute of toluene-methanol (96:4). Aliquots were then analyzed. 
Instrumentation: Gas chromatography was performed on a 30 m x 0.25 mm tD fused 
silica column with a chemically bonded stationary phase Sil 5 CB (J.W. lnterscience, 
Breda, The Netherlands). Splitless injection and nitrogen-phosphorus sensitive detection 
were applied. Initial oven temperature was 120°C for 0.6 min, followed by a rise of 
30°C/min to 280°C; the final stage of 280°C lasted 7 min. Injector and detection 
temperatures were 280°C and 300°C, respectively. Helium was used as carrier gas at a 
gas flow of 3 ml!min. 
The limit of quantification was 1 ng/ml. 
Data analysis: Pharmacokinetics were analyzed by the Nonlin-computer program. The 
individual plasma concentration-time curves were fitted to 2 exponential terms for most 
subjects; just for subject H mono-exponentiona! fitting was the best option. Using the 
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fitted plasma concentration-time curve the following parameters were calculated: the 
elimination half-life (t~) from the time constant in the second exponential term; the 
clearance (CI) from the ratio dose/area under the curve (AUC); the mean residence time 
(MRT) from the ratio of the area under the "concentration x time versus time" curve 
{TAUC) to the AUC; and the volume of distribution from the product of the MRT and 
the clearance (12, 13). 
RESULTS 
The individual values for the pharmacokinetics of flumazenil are given in table 1. Rapid 
pharmacokinetics were demonstrated for the healthy volunteers with elimination half-
life times of about 1 hour and slightly longer mean residence times. For the patients 
with liver disease t"' varied between 2 and 6.6 hours, i.e. up to 6 times the values 
determined for controls, with the highest values found for the patients with acute liver 
insufficiency. Mean residence times were similarly prolonged in liver failure. The plasma 
clearance rates for patients were decreased 3-5 fold: from 700-850 ml!min for controls 
to 120-320 ml!min in liver failure. No differences in the volumes of distribution could be 
demonstrated between controls and patients with liver disease. For patients with-liver 
disease, the clearance rate of flumazenil was related to the plasma antithrombin Ill 
level, a parameter for the assessment of liver function (r5 =0.943, p<0.05). 
DISCUSSION 
We have demonstrated markedly impaired pharmacokinetics of flumazenil in severe liver 
disease, in cirrhosis as well as hepatitis. Our findings for severe liver disease are similar 
to published values for Child Cliver cirrhosis (14). As in our study plasma clearance 
rates showed about a 4-fold decrease and elimination half-lives about a 4-fold increase 
in patients with Child C liver disease (14). In a study on pharmacokinetics in less severe 
liver disease, plasma clearance rates were about 2 times decreased and elimination 
half-lives about 2 times increased (15). Our assessment of the elimination kinetics of 
flumazenil for healthy volunteers is again similar to that reported by others (8-11). 
Elimination kinetics of flumazenil have been demonstrated to be linear over a wide dose 
Table 1: Individual parameters of liver disease and disposition kinetics of flumazenil. 
acute hepatitis liver cirrhosis 
subject A B c D E 
sex F M F F F 
age (yl 18 18 18 61 65 
albumin (g/1, N 36-481 31 31 30 21 25 
antithrombin Ill (U/1, N > 85) 0.10 0.01 # 0.52 0.23 
bilirubin (pM, N < 121 196 556 457 393 42 
ASAT (U/1, N < 30) 94 330 304 109 50 
pharmacokinetics 
t, (hr) 2.25 6.56 5.59 2.32 2.08 
MRT (hrl 2.98 9.39 8.08 3.28 2.98 
Cl (ml/minl 261 144 122 322 272 
v$~ m 46.5 81.0 59.1 63.3 48.5 
v .. (1/kg) • • • 0.88 0.97 
# not detectable in plasma; * body weight not available for cases with severe disease 
F G 
M F 
38 28 
31 47 
0.20 1.09 
602 11 
109 18 
3.16 1.21 
4.53 1.45 
218 858 
59.1 74.5 
0.86 1.26 
healthy volunteers 
H I 
F M 
28 36 
44 49 
1.12 1.23 
7 11 
16 16 
0.74 0.99 
1.07 1.10 
724 720 
46.6 47.5 
0.78 0.63 
J 
F 
36 
44 
1.12 
7 
18 
0.85 
1.05 
694 
43.5 
0.79 
"' 
..., 
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range (2.5-40 mg iv) (8-11). Therefore, we felt it was justified to give the control sub-
jects a double dose, thereby enhancing the sensitivity of the analysis. 
Flumazenil is eliminated from the body almost exclusively by the liver (8). The high 
clearance rate in healthy subjects suggests that extraction of the drug by the liver is at 
least partly blood flow-dependent (8-9). The pharmacokinetics of drugs for which the 
hepatic clearance is determined by liver blood flow in the healthy state may become 
dependent on liver function in the event of liver disease (16). The correlation between 
the plasma clearance of flumazenil and the plasma levels of antithrombin Ill in patients 
with liver disease supports the relation between clearance and liver cell function. A 
relation between the plasma clearance rate of flumazenil and the Child Pugh score has 
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Figure 1: Plasma concentration~time curves: a patient with acute 
hepatitis (subject C, -----), a patient with liver cirrhosis (subject F, 
······L a volunteer (subject J, --). 
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also recently been demonstrated (14). 
To our knowledge, dose-response studies on the use of flumazenil to antagonize 
benzodiazepines in liver disease have not yet been published. Plasma concentrations of 
flumazenil between 10 and 20 ng/m[ have been recommended for antagonism of 
benzodiazepines in healthy subjects (17). For situations in which prolonged antagonism 
of benzodiazepines is indicated, an infusion rate of 1.44 mg of flumazenil/hr has been 
calculated (17). Assuming a similar flumazenil plasma concentration-effect relationship 
in individuals with and without liver disease, a lower rate of infusion of flumazeni[ 
would suffice for antagonism of benzodiazepines in patients with severe liver disease. 
According to the equation dose::;: clearance x plasma steady state concentration, an 
infusion rate of 0.1-0.3 mg/hr would then be sufficient to reach steady state con-
centrations of 15 ng/ml, assuming clearance rates of 120 and 320 ml/min, respectively. 
Higher infusion rates would indeed be recommended for patients with less severe liver 
disease. However, because the elimination of benzodiazepines in liver disease is 
markedly impaired (18), treatment with flumazeni! may be necessary for longer periods 
than in health. 
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Chapter 8 
FACTORS CORRELATED WITH ENCEPHALOPATHY IN LIVER DISEASE: 
A LOGISTIC REGRESSION ANALYSIS 
The contents of this chapter have been submitted for publication under the same tit!e 
with the following authors: C.C.D. van der Rijt, P. Mulder, S.W. Schalm, E.P. Krenning 
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ABSTRACT 
Studies on the pathogenesis of hepatic encephalopathy often reveal discrepancies 
between the levels of specific toxins and the presence of encephalopathy. In order to 
investigate the contribution of the metabolic disturbances frequently encountered in 
complicated liver disease to the pathogenesis of encephalopathy in liver disease, we 
performed a case-control study. A comparison between twenty six patients with liver 
disease and encephalopathy and 26 controls with liver disease without encephalopathy 
of their vital signs (temperature, heart rate and blood pressure), complications of portal 
hypertension, alcohol consumption and, predominantly routine, laboratory 
determinations was carried out. There was no significant difference in vital signs 
between the two study groups. Patients with encephalopathy had more severe ascites 
and consumed more alcohol. Of the 43 laboratory determinations studied, 19 were 
significantly different between the two study groups; they included indicators of liver 
cell damage, liver protein synthesis, liver detoxification, infection and renal function as 
well as zinc, glucose, vitamin, thyroid hormone, cortisol and prolactine levels. Starting 
with variables with a p-I eve I < 0.005 in the univariate analysis, logistic regression 
analysis was performed using a backwards selection procedure. The granulocyte count, 
zinc concentration, massive ascites and T3 level were selected as predictive variables. 
Starting with these variables, the contribution of the variables with p-levels between 
0.05 and 0.005 was tested using a forward procedure. Heavy alcohol consumption 
contributed significantly to the model and replaced the variable granulocytes. The 
possible relationships between the selected variables and encephalopathy in liver 
disease, whether directly causal or an epiphenomenon, are discussed. 
INTRODUCTION 
Encephalopathy is a serious complication of acute and chronic liver disease. Many 
studies on the pathogenesis of hepatic encephalopathy have focused on specific toxins 
that are not adequately metabolized by the diseased liver (ammonia, GABA, 
mercaptans, free fatty acids). However, several discrepancies have been found 
between the plasma levels of specific toxins and the grade of hepatic encephalopathy. 
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In acute hepatic failure as well as chronic liver disease, complications can occur in 
several organ systems; renal fai!ure is especially common (1-2). But acid-base 
disturbances, electrolyte abnormalities, infections and oxygen deficiency are also often 
encountered (3-5). Nutritional deficiences have been found, especially in chronic liver 
disease {6). Since each of these complications alone can induce encephalopathy (7), 
they may also contribute to the encephalopathy in liver failure, possibly together with 
specific toxins. The impact of a combination of factors has received little attention. 
Logistic regression analysis has been used in epidemiology to study the predictive value 
of a combination of variables for the occurrence of a disease state. To gain more 
insight into which factors are related to the encephalopathy of liver disease in clinical 
practice, we performed a case-control study of patients with !iver disease with and 
without encephalopathy. A set of independent variables that were closely correlated 
with encephalopathy was selected by logistic regression analysis. 
PATIENTS AND METHODS 
Patients: Two groups of patients with acute or chronic liver disease were selected for 
the study. The first group consisted of 26 cases of liver disease and hepatic 
encephalopathy; the second group comprised 26 controls with liver disease but without 
hepatic encephalopathy. The two groups of patients were similar in age (47 ± 17 yr 
(group 1) vs. 49 ± 16 yr (group 2); mean± S.D.) and sex (males:females; 17:9 (group 1) 
vs. 19:7 (group 2)). Four of the 26 subjects from group 1 presented with hepatitis, 1 
with steatosis of the liver and 20 with cirrhosis. Histological confirmation was available 
for all but 3 patients with cirrhosis and 1 patient with unknown liver disease. For the 
patients in the 2nd group, the underlying liver disease was hepatitis in 3, chronic 
hepatitis or steatosis of the liver in 3 and cirrhosis in 20 subjects {3 without histology). 
The etiology of the liver disease was alcoholic (group 1 vs 2: 9 vs 7), viral (6 vs 6), 
auto-immune (1 vs 3), toxic {1 subject in group 2), primary biliary cirrhosis (1 vs 2), 
secondary biliary cirrhosis (2 in group 2), Wilson's disease (1 in group 2), poly-arteritis 
nodosa (1 in group 2) or unknown/cryptogenic (9 vs 3). Two patients in each group 
had received a surgical portocaval shunt. All subjects were hospitalized at the time of 
the study. There was no significant difference between the two groups in the duration 
of admission before entrance into the study {4.3±6.0 days (group 1) vs. 3.3±3.5 days 
104 
(group 2); mean±S.D.). 
Study-design: A case-control study was performed between November 1987 and April 
1989. Every patient with known acute or chronic liver disease and clinically evident 
encephalopathy admitted by the Department of Internal Medicine II was considered a 
case. When such a patient was identified, the next patient with liver disease but 
without encephalopathy admitted to our hospital was included in the study as a control. 
The selection of patients was irrespective of sex, age, severity and etiology of the 
underlying liver disease. Only patients with a malignancy, if already known during the 
selection procedure, were excluded from the study. The study did not interfere with the 
therapeutic strategy for the patients. 
The presence of clinically evident encephalopathy was assessed by the first author. 
Temperature, pulse rate and blood pressure were recorded on the day of the study. The 
medical records were studied to evaluate the complications of portal hypertension; 
ascites was graded as absent, present or massive on the basis of physical examination 
and echography; esophageal varices, graded as absent or present, were evaluated by 
means of esophagoscopy or radiology; portal collaterals, graded as absent or present, 
were investigated by echography; and the length of the spleen was measured by 
echography. Drugs used by the patients were recorded, with special attention to the 
actual use of lactulose and/or neomycin and diuretics. The number of alcoholic 
beverages consumed each week was also noted (table 1 ). 
On the day the patient was evaluated for the presence or absence of encephalopathy, 
blood was drawn for a number of, predominantly routine, laboratory determinations 
(table 2). They represented assessment of a wide range of metabolic functions, 
including hepatic function itself (liver cell damage, protein synthesis and detoxification). 
A list of the causes of metabolic encephalopathy, as published by Plum and Posner (7), 
was used as a reference for the choice of variables. 
Clinical grading of encephalopathy: Grade 0 encephalopathy was defined as the 
absence of at least 3 of the following abnormalities: inverted sleep pattern, disturbed 
memory, impaired calculation {serial 7'sl and slowness of speech; grade 1 as the 
presence of at least two of these abnormalities (one abnormality in association with a 
flapping tremor was also classified as grade 1 ); grade 2 as the presence of at least 2 of 
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the following: lethargy .. disorientation in time and flapping tremor; grade 3 as the 
presence of at least two of the following: a state in which the subject must be urged 
repeatedly to open his eyes or execute a command, disorientation in place and loss of 
self; and grade 4 as coma. 
Table 1: Patient characteristics 
group 1 group 2 group 1 group 2 
frequency frequency p mean SEM nr mean SEM nr 
hepatic encephalopathy 
grade 0 26 
grade 1 5 
grade 2 7 
grade 3 4 
grade 4 10 
lactulose and/or neomycin 22 14 0.04 
diuretics 9 13 
glucocorticoids 4 3 
dopamine o· 0 
alcohol (drinks/week) 0.01 
0 12 21 
1·14 3 3 
>14 8 1 
unknown 3 
ascites 0.003 
absent 4 14 
present 9 9 
massive 13 3 
esophageal varices 
absent 5 7 
present 16 15 
unknown 3 3 
venous col!aterals 
absent 12 17 
present 10 9 
unknown 4 0 
spleen (in em) 15 1 122) 13 1 126) 
temperature {°C) 36.5 0.1 126) 36.8 0.1 126) 
heart rate (bpm) 90 3 126) 83 3 126) 
blood pressure {mm Hg) 
systolic 128 4 126) 140 5 126) 
diastolic 75 3 126) 82 3 126) 
•: 2 patients had been treaten with dopamine the day before inclusion. 
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Statistical analysis: The difference in each variable between the two groups of patients 
(group 1 with and group 2 without hepatic encephalopathy) was tested by the two-
sample Wilcoxon test or the Chi-square test. Variables that were significantly different 
were selected for logistic regression analysis in an attempt to discriminate between the 
two groups of patients. Each group was assumed to be a random sample of an 
underlying population, I and It, respectively. In the analysis the probability that a patient 
belonged to either of the two populations (say population I) was expressed as a logistic 
discriminant function of the explanatory variables x,, ... ,xn: 
P[pop.IJ x,, ... ,xol={1 +exp(-130-13,x,- ... -130X 0 }-1 
The 13-coefficients were estimated by means of a maximum likelihood estimation 
method. Variables with p<0.1 in the likelihood ratio test were selected for the model. 
A 1'1-coefficient can be interpreted as being the logarithm of the odds ratio related to an 
increase of one unit in the corresponding x-variable. The odds is defined here as the 
probability of belonging to population I versus the probability of belonging to population 
II; the odds ratio is the factor by which the odds must be multiplied when a variable 
increases by one unit, the other variables remaining constant. 
RESULTS 
According to table 1, patients with hepatic encephalopathy presented with more severe 
ascites, consumed more alcohol and were treated with lactulose and/or neomycin more 
often than the controls. No significant differences were observed in the parameters of 
portal hypertension other than ascites. 
There was a significant difference in the results of nineteen of the 43 laboratory 
determinations performed between cases and controls (table 2). They represented 
parameters of liver cell damage (ASATL liver synthesis (Thrombotest, Normotest, 
antithrombin 3L liver detoxification (ammonia, bilirubin), infection (total leukocytes, 
granulocytes, monocytes), renal function (creatinine) and endocrinologic function (T3, 
•Legend to table 2: 
•: plasma calcium level corrected for albumin 
levels of significance 1):p<0.05; 2J:p<0.01; 3J:p<0.005; 4):p<0.001 
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Table 2: Laboratory measurements in the case~control study 
group 1 group 2 
mean SEM nr mean SEM nr p 
Quantitative liver function 
liver ce!l damage: 
ASAT IU/11 207 45 1261 99 19 1261 1 I 
ALAT {U/Il 385 156 1261 87 17 1261 
alk.phosphatase (U/1) 135 10 1261 185 23 1261 
synthesis: 
albumin (g/IJ 26 1 1261 30 1 1261 1 I 
total protein (g/1 64 2 1261 68 2 1261 
Thrombotest (%) 21 2 1251 42 3 1261 41 
Normotest (%) 28 3 1251 57 5 1261 41 
antithrombin 3 (U/ml} 0.34 0.04 1251 0.60 0.06 1261 31 
detoxification: 
NH3 IJJMI 118 11 1261 74 6 1261 31 
bilirubin (JJM) 258 41 1261 103 29 1261 41 
bile acids WMJ 134 21 1251 102 16 1261 
Quantitative non-hepatic metabolic function 
hematology 
hemoglobin {mM Fe} 7.4 0.2 1261 7.6 0.2 1261 
thrombocytes (109 /1) 133 20 1251 152 21 1251 
leukocytes {1 09/ll 13.2 1.6 1261 7.5 0.9 1261 41 
granulocytes (10911) 11.1 1.4 1251 5.5 0.8 1251 41 
lymphocytes (1 09/]) 1.5 0.2 1251 1.5 0.2 1251 
monocytes (1 0 9/1) 0.9 0.1 1251 0.6 0.1 1251 1 I 
plasma viscosity {Cstl 1.25 0.04 1221 1.32 0.01 1261 
FOP's (% >10 mg/1) 29 40 
chemistry 
urea (mMJ 13.7 2.4 1261 7.3 1.0 1261 
creatinin (pM) 187 37 1261 89 6 1261 1 I 
K (mM) 4.2 0.2 1261 4.1 0.1 1261 
Na(mM) 137 1 1261 139 1 1261 
Ca(mMJ• 2.35 0.04 1261 2.35 0.02 1261 
P041mMI 1.19 0.12 (261 1.03 0.03 1261 
zinc (tlg/1 OOml) 48 4 (221 66 4 1251 31 
Mg (mM) 0.90 0.04 1251 0.83 0.02 1261 
osmolality (mosmol/kg) 292 4 1261 286 2 (261 
glucose (mM) 6.2 0.3 1261 5.4 0.5 1261 21 
p02 (kPa) 11 .2 0.6 1251 12.4 0.5 1251 
PC02 (kPal 3.9 0.1 1251 4.2 0.1 1251 
PH 7.46 0.01 1251 7.45 0.01 (251 
vitamin 81 (pM) 161 19 1221 108 10 1261 
vitamin 82 (pM) 0.33 0.02 1231 0.31 0.01 (261 
vitamin 86 (pM) 147 15 121 I 96 8 1241 31 
vitamin 812 (nM) 912 39 121 I 655 55 1251 31 
folic acid (nM) 15 3 1201 19 3 1251 
endocrinology 
T3 (nmollll 0.47 0.06 (251 1.21 0.11 1261 41 
T4 {nmolll) 61 8 1261 91 7 1261 31 
T3/T4 0.008 1251 0.014 1261 41 
TSH {mUll) 4.04 2.51 1251 1.90 0.23 1261 
cortisol 9.00 hr.A.M.{nM) 699 95 1231 457 43 (261 1 I 
prolactin (pg/[) 16.2 3.2 1261 8.0 0.7 (261 1 I 
plasma benzodiazepine 
(% positive) 32 31 
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T4, cortisol and prolactin) as well as zinc, glucose and vitamin (86 and 812) 
concentrations. 
Simultaneous inclusion of all variables that yielded a significant difference of p<0.05 
between the two groups of patients in the logistic regression analysis could not be 
justified in view of the total number of patients and the risk of overidentification. The 
first selection of variables to be excluded from further analysis was based on 
theoretical grounds; glucose and vitamins 86 and 812 were rejected as variables for 
further analysis because their levels did not indicate hypoglycemia, hyperglycemia or 
deficiences, respectively. Next, variables were selected on the basis of a p-level 
<0.005 in the univariate analysis. Among the variables thus under consideration were 
thrombotest, normotest and antithrombin 3, all of which represent liver protein 
synthesis, leukocytes and granulocytes, which represent infection, and the variables of 
thyroid function, T3, T4 and the ratio T3!r4. Further selection, therefore, was 
performed by applying logistic regression analysis to these three sets of variables. 
Thrombotest from the first set, granulocytes from the second set and T3 from the last 
performed the best. Ultimately, 7 variables were included in the logistic regression 
analysis: ascites, thrombotest, ammonia, bilirubin, granulocytes, zinc and T3. Starting 
with a full model including all of these variables it appeared from a backwards selection 
procedure that hepatic encephalopathy was best predicted by the presence or absence 
of severe ascites, granulocytes, zinc and T3 (table 3). The predictive value of these 
variables together was 93.2% 
The predictive values of variables with p-values in the univariate analysis between 0.05 
and 0.005 were investigated in a second logistic regression analysis. Starting with the 
variables selected by the first analysis, the contribution of the variables alcohol, 
albumin, ASAT, creatinine, cortisol and prolactine was tested using a forward 
procedure. Only the frequent use of alcohol contributed significantly to the model, even 
replacing the variable granulocytes. The presence of severe ascites, heavy drinking and 
low levels of zinc and T3 predicted the correct group for 95% of patients (table 3). 
Table 3: Results of logistic regression analysis 
variables studied SE odds ratio 
1. Backward selection procedure for variables with p<O.OOS 
included: 
massive ascitis 
granulocytes 
zinc 
T3 
excluded 
mild ascitis 
ammonia 
bilirubin 
thrombotest 
2. final model 
included 
massive ascitis 
T3 
heavy drinking 
zinc 
excluded 
thrombotest 
mild ascitis 
ammonia 
cortisol 
2.59 
0.32 
-0.08 
-7.01 
2.82 
-8.61 
4.91 
-0.05 
1.56 
0.24 
0.04 
3.10 
1.76 
4.07 
3.43 
0.04 
13.29 
1.38 
0.93 
0.0009 
16.74 
0.0002 
135.49 
0.95 
p 
0.06 
0.06 
0.01 
0.0003 
0.06 
0.0003 
0.03 
0.05 
B-coefficient=logarithm of the odds ratio; SE=standard error of the B-
coefficient; odds ratio =the factor by which the odds must be multiplied when 
the corresponding variable increases by one unit; p =significance of the 
likelihood ratio test. 
DISCUSSION 
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We performed a case-control study to gain more insight into the factors related to 
hepatic encephalopathy. Because several discrepancies have been found between 
specific toxins and the grade of hepatic encephalopathy, we were especially interested 
in the contribution of several metabolic disturbances that have been related to the 
frequent complications of severe liver disease. Granulocytes or heavy alcohol 
consumption, massive ascites, serum zinc and serum T3 were selected by logistic 
regression analysis. Several complications often found in liver disease, especially renal 
failure, electrolyte abnormalities, acid-base disturbances and nutritional deficiences, 
were not selected. Although there was a significant difference in the level of ammonia, 
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often considered the major toxin in the pathogenesis of hepatic encephalopathy, 
between the two groups of patients studied, ammonia was excluded from the model by 
logistic regression analysis. 
Logistic regression analysis is often used in epidemiology to identify cause·effect 
relationships. In our study it is important to realize that different mechanisms might 
explain a correlation between a variable and encephalopathy. In theory three 
explanations have to be considered (figure 1 ): the variable may indeed be causally 
related (a); the variable may be the result of encephalopathy (b); or the variable may be 
an epiphenomenon: i.e. it might be related to a third factor, which is more directly 
related to encephalopathy in liver disease (c). 
The number of granulocytes contributed significantly in the prediction of the presence 
of encephalopathy in our study population. However, after inclusion of alcohol 
consumption in the logistic regression analysis, granulocyte counts were excluded from 
the model, suggesting a correlation between granulocytes and alcohol abuse. How can 
a. b. 
v E E ~v 
c. 
F ~E 
or 
Figure 1: Theoretical mechanisms for the relation between a variable and encephalopathy; a: 
the variable {V) is causally related to the encephalopathy (E); b: the variable is the result of the 
encephalopathy; c: the variable is related to a third factor (F) which is directly related to the 
encephalopathy. 
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we explain this correlation and how can we explain its relation to encephalopathy in 
liver disease? 
Alcohol has been reported to be a frequent precipitating factor in hepatic 
encephalopathy (9-10). The abuse of alcohol may facilitate endotoxemia by impairing 
Kupffer cell function (11), inducing bacterial overgrowth in the small intestine (12) 
and/or increasing the permeability of the intestinal wall (13). Previous studies have 
shown elevated titers of Escherichia coli antibodies in particular in alcoholic hepatitis 
(14) and a relation between endotoxemia and alcohol consumption in health and liver 
disease (15). Endotoxins may indeed cause granulocytosis. Furthermore, experimental 
studies have indicated that liver failure and hepatic encephalopathy can be induced by 
the injection of endotoxin (16-17). In clinical studies an increased incidence of 
endotoxemia has bee.n found for patients with hepatic encephalopathy (18). 
liver failure alcoholism 
l / 
endotoxinemia 
1 
monocytes 
cytokine production 
/ ~ 
? 
granulocytosis encephalopathy 
Figure 2: Hypothetical model explaining the relation between alcohol abuse, leukocytes and 
encephalopathy. 
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Alcoholic hepatitis has also been associated with the enhanced production of cytokines 
by monocytes, especially interleukin-1 and tumor necrosis factor (TNF) (19-20); the 
presence of TNF has been said to predict a poor prognosis (21 ). We could therefore 
hypothesize that alcohol induces cytokines, with or without endotoxemia, which 
subsequently cause granulocytosis and hepatic encephalopathy. As shown in figure 2, 
granulocytosis is presumed to be an epiphenomenon. 
What is the relationship between the serum zinc level and hepatic encephalopathy? The 
total serum zinc concentration is the net result of the zinc status in the body, the serum 
binding proteins and serum factors that modify zinc-protein binding (22-23). Normally, 
a major fraction of zinc is "loosely" bound to albumin; a smaller fraction is "tightly" 
bound to a 2-macroglobulin. In decompensated liver disease the concentration of zinc 
bound to a2-macroglobulin is increased (23). Decreased serum zinc levels in patients 
with encephalopathy may therefore represent either zinc deficiency or diminished 
albumin synthesis. Since the logistic regression analysis excluded albumin and the other 
variable of liver cell protein synthesis, thrombotest, from the model, serum zinc may 
not only represent protein binding but also zinc deficiency in encephalopathy. 
The idea of zinc defiency as a causative factor in hepatic en cephal apathy is supported 
by our recently published case report on hepatic encephalopathy (24). We described a 
woman with chronic recurrent portosystemic encephalopathy resistent to the standard 
therapy of protein restriction and lactulose. L-histidine-induced zinc loss caused an 
episode of hepatic encephalopathy similar to previous episodes, and chronic therapy 
with zinc substitution improved her quality of life. Furthermore, zinc supplements 
appeared to improve mild hepatic encephalopathy in a randomized clinical trial (25). 
The finding of massive ascites turned out to be an important predictor of hepatic 
encephalopathy. Several explanations can be considered for this relation. Ascites and 
hepatic encephalopathy are both predictors of a poor prognosis for severe liver disease. 
Therefore, the correlation may not be a cause-effect relation; instead ascites and 
encephalopathy may be two (related) prognostic variables. The frequent use of diuretics 
for the treatment of ascites might also explain the correlation between ascites and 
encephalopathy, since diuretics have been reported to induce hepatic encephalopathy 
(26). However, in this study about the same numbers of patients in the two groups 
were treated with diuretics. 
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Ascites in liver disease has been associated with a hyperdynamic circulation and 
reduced systemic vascular peripheral resistance (27). Diminished hepatic metabolism of 
a vasodilator substance generated in the splanchnic bed has been proposed as the 
etiologic mechanism leading to the hyperkinetic circulatory state (27·28). S. Sherlock 
recently discussed the possible contribution of the altered circulatory state to the 
development of the hepatorenai and hepatopulmonary syndrome and its possible role in 
cerebral edema (29). Hepatic encephalopathy has been found to be associated with 
elevated serum levels of substance P (30) and prostacyclin synthesis stimulating factor 
(31 ) .. both of which have an important vasodilatory effect. The correlation between 
ascites and hepatic encephalopathy might therefore be explained by a similarity in 
etiologic factors, i.e. substances with vasodilatory as well as cerebral actions (figure 3). 
Not only vasodilators but also vasoconstricting agents, especially norepinephrine and 
liver failure 
1 
blood J 
vasodilatory 
compounds 
increased 
? 
encephalopathy 
effective blood volume 
decreased 
l 
renin-angiotensin-aldosteron 
noradrenalin/ adrenal in 
antidiuretic hormone 
increased 
~1 
ascites 
Figure 3: Hypothetical model explaining the relation between ascites and encephalopathy. 
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the renin-angiotensin~aldosteron system, are found in elevated concentrations in 
patients with ascites and liver failure (27). As far as the authors know, no reports on 
an association of these factors with hepatic encephalopathy have been published. 
The level of T3 was strongly correlated with encephalopathy in liver disease. What 
causes this relationship? Serum T3 is largely protein-bound. It is generated in the liver 
from thyroxine, which enters the liver via specific receptors (32). Decreased T3 levels 
may therefore represent diminished protein binding, decreased T4 transport into the 
hepatocyte and diminished intracellular metabolism. The contribution of protein binding 
may be eliminated by using the ratio of the thyroid hormones T3 and T4, since these 
two hormones bind to the same serum proteins with almost similar affinities {32). 
Testing the difference in the ratio T3/T4 between the two study groups yielded a p-
3 
- 0 _J 
' 
0 
0 
0 2 E 
c 0 0 
-
0 
CIJ 0 I-
1 b 
0 
0 bO 
.6. A 1:::.1:::. 
b 0 0 
b b 
AAJ:::. /::./::. 1:::. 
b 
0 b 
0 20 40 60 80 
thrombotest {%) 
Figure 4: Relation between serum T3 levels and thrombotest as a parameter of liver 
function for the entire group of patients studied (~:group 1; o:group 2; r=0.87, p =0.012). 
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level of significance of 0.0001 (mean±S.D., group 1 0.008±0.004; group 2 
0.014±0.0051. Decreased T3 levels, therefore, cannot be explained by diminished 
protein binding alone. 
Decreased T4 transport across the cell membrane and diminished intraceUular 
metabolism of T4 into T3 may represent liver function. Correlations between T3 levers 
and the parameters of liver function have indeed been reported (33). We also found a 
significant relationship between T3 and thrombotest in this study (figure 4). However, 
low thyroid hormone concentrations are atso found in a variety of nonthyroidal illnesses 
other than liver disease (34). Correlations between the indices of thyroid function, 
especially T3 and T4, and markers of the severity of the underlying disease have been 
demonstrated in general (35-36). Therefore, what causes the relationship between T3 
and encephalopathy? Is it related to liver function or the severity of disease in genera!, 
or can thyroid hormones be causatly related to encephalopathy? Preliminary findings 
seem to indicate that liver function alone cannot explain the relationship. Substituting 
the ratio T3!T4 for T3 in the first backwards procedure of the logistic regression 
analysis, we found that thrombotest and the ratio were both selected instead of T3 
alone. 
The relation between T3 and encephalopathy in liver disease may represent T4 
transport across the cell membrane and thus may be an indirect re[ationship (T3 as an 
epiphenomenon). A study of T4 liver plasma membrane transport seems worthwhile. ln 
mouse neuroblastoma ce!!s L-amina acids were shown to be competitive inhibitors of 
thyroxine transport across the cell membrane (37). If the thyroxine binding protein of 
the liver is similar to that of neurons, those L-amina acids which are increased in 
hepatic encephalopathy (phenylalanine, tyrosine and tryptophane) may inhibit T4 uptake 
in brain as well as the liver and hence contribute to the low serum T3 levels (figure 5). 
In that case, the role of L-amina acids in the pathogenesis of hepatic encephalopathy 
may have to be reconsidered. 
Can thyroid hormones be causally related to encephalopathy? T3 instead of T4 was 
selected as a predictor for the presence of encephalopathy. However, in contrast to 
peripheral tissues, the cells of the central nervous system do not obtain most of their 
T3 by direct cellular uptake but from de-iodination of T4 {38). Decreased availability of 
T3 in the neuronal cell due to low serum levels therefore seems unlikely but diminished 
T4 uptake in neuronal cells may induce deficient intracellular T3 levels. Furthermore, 
the non-metabolic roles for thyroid hormones in the central nervous system are as yet 
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liver failure 
~l 
liver 
T4-uptake 
T 4-metabolism 
diminished 
blood 
aromatic 
brain 
amino acid T 4-uptake 
increased diminished 
? ~? j? T3 levels . ~ 
diminished-- encephalopathy 
Rgure 5: Hypotheses for the relation between serum T3 and encephalopathy. In a, T3 is a 
causal factor of encephalopathy; in b and c T3 is an epiphenomenon. 
poorly defined, but several studies have demonstrated modulatory effects on 
neurotransmission, especially glutamate and benzodiazepine receptors (39-41 ). Since 
correlations between thyroid hormones and encephalopathy without liver disease have 
also been reported (Glasgow Coma Scale ratings for traumatic brain injury) (42), further 
studies on the role of T3 and T4 in central nervous system functioning are needed. 
Of the variables excluded during logistic regression analysis, ammonia is the one most 
often related to hepatic encephalopathy. As mentioned earlier, our study did not 
interfere with the therapeutic strategy for these patients. Patients with hepatic 
encephalopathy were indeed treated with Jactulose and/or neomycin more often than 
the controls. Therefore, we cannot conclude from this study that ammonia does not 
induce hepatic encephalopathy in general. Furthermore, previous studies have already 
demonstrated that the correlation between hepatic encephalopathy and ammonia levels 
is better immediately after admittance than later during hospitalization (43). The 
possibility of a role for ammonia is further substantiated by the close correlation 
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between glutamine levels in cerebrospinal fluid and encephalopathy (44-45). 
In conclusion, our case-control study yielded the variables granulocytes and alcohol, 
zinc, massive ascites and T3 as predictors for the presence of encephalopathy in liver 
disease. A case-control study, however, cannot be the ultimate proof for theories on 
pathogenesis. Further prospective studies are needed to investigate the selected 
variables in new groups of patients. Furthermore, the effect of active interference with 
the suggested factors has to be studied. 
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Chapter 9 
OVERT HEPATIC ENCEPHALOPATHY PRECIPITATED BY ZINC DEFICIENCY. 
A CASE REPORT 
The contents of this chapter have been published in Gastroentero!ogy (1991; 1 00:1114-
1118) under the same title with the following authors: C. C. D. van der Rijt, S.W. Schalm, 
H. Schat. K. Foeken, G. de Jong. 
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ABSTRACT 
Encephalopathy in liver disease may be unresponsive to protein restriction, lactulose and 
neomycin. Zinc supplements have been reported to improve psychometric performance in 
liver cirrhosis but the importance of zinc deficiency in overt hepatic encephalopathy has not 
yet been clearly established. We studied a patient with severe recurrent hepatic 
encephalopathy to determine the relation between her signs of encephalopathy and zinc 
deficiency. The study included a period in which zinc deficiency was artificially induced by 
oral histidine. An episode of overt encephalopathy occurred that was identical to earlier 
episodes and responded to oral zinc. The study showed an association between 
encephalopathy and zinc deficiency by successive zinc depletion and supplementation 
regimens. Long term zinc supplementation improved severe recurrent hepatic 
encephalopathy and thereby the quality of life. 
INTRODUCTION 
Encephalopathy is a complication of acute and chronic liver failure. Its pathogenesis is still 
unresolved but the accumulation of gut-derived nitrogenous substances due to impaired 
hepatic clearance is generally thought to be a major mechanism (1 ). Protein restriction, 
!actulose and neomycin, given to reduce the production of nitrogenous toxins .. are effective 
in some but not all patients (1 ). 
ln patients without liver disease zinc deficiency may induce neurological and psychiatric 
symptoms: ataxia, lethargy, depression and hallucinations (2-4). ln liver disease the 
concentrations of zinc in serum (5).. leukocytes (6) and liver (7) are decreased. The 
importance of zinc deficiency in hepatic encephalopathy has not yet been clearly 
established .. although zinc supplements have been reported to improve mild chronic hepatic 
encephalopathy, as measured by psychometric testing (8-10), as well as some.episodes 
of hepatic encephalopathy following gastro-intestinal bleeding (11 ). 
We have studied a patient with incapacitating recurrent hepatic encephalopathy to 
determine the relation between her signs of encephalopathy and markers of zinc deficiency. 
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CASE REPORT 
A 54-year-old woman with congenital liver fibrosis was admitted for evaluation of the need 
for liver transplantation because of recurrent episodes of hepatic encephalopathy. Fifteen 
years previously she had undergone a side-to-side porto-cava[ shunt operation for recurrent 
severe bleeding from esophageal varices. After surgery she remained we!! until 5 years ago 
when the first episode of encephalopathy occurred. Since then episodes of encephalopathy 
have recurred with increasing frequency (6 episodes in the 6 months prior to admission) 
despite a low protein diet, lactulose and neomycin. According to her husband a typical 
episode was preceded by a short period in which she vigorously cleaned the house. She 
then complained of a tremor around the mouth, nausea and vomiting, and subsequently 
slept for one or more days. During this latter period she did not eat or drink and was unable 
to speak or walk. Handling her caused aggressive resistance. She was sometimes 
incontinent. Upon awakening she again felt nauseated. Afterwards ~he had a total amnesia 
for the episode. 
Upon admission to our hospital mental signs of hepatic encephalopathy were not obvious 
although a slowness of speech was noted. Neurological examination revealed a mild high-
frequency tremor (but not a flapping tremor) and impaired heel-toe walking without other 
abnormalities. Electroencephalography demonstrated an alpha rhythm of 8c/s; the mean 
dominant frequency (MDF) as measured by spectral analysis of the EEG was 8.5 Hz. 
Biochemical analysis was consistent with a diagnosis of chronic stable liver disease 
(bilirubin 36pmol/l, alkaline phosphatase 259 U/1, gamma-GT 173 U~, ASAT 55 U/1, ALAT 
55 U/1, albumin 29 g/1 and prothrombin time 21 sec, which is 3 sec above normal). The 
arterial plasma ammonia level was 108 pmol/1. A search for encephalopathy-inducing 
metabolic or structural disturbances revealed a depressed serum zinc level: 34 pg/dl 
(normai80-150 pg/dl). She was observed for 6 weeks without changing her treatment with 
protein restriction (60 grams/day), lactulose (60 ml/day) and neomycin (4 g/day). An 
episode of encephalopathy did not occur, despite spontaneous fluctuations of the arterial 
ammonia level between 83 and 1 65 pmoi/L To examine her protein tolerance the protein 
intake was increased to 100 grams/day for one week. After 3 days her speech became 
slurred and her gait wide-based. However, no deterioration could be detected in the 
electroencephalogram. The symptoms resolved spontaneously, despite continuation of the 
1 00-gram protein diet. She was then given zinc acetate (600 mg/day orally for 3 weeks) 
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to correct the possible zinc deficiency and hopefully to prevent new episodes of 
encephalopathy after discharge from the hospital. During this period serum zinc rose from 
46 to 91 pg/1 and the activity of the serum zinc-dependent enzyme alkaline phosphatase 
increased from 257 to 404 U/1 (normal < 100 U/1). 
For 2 months she felt very well and had no new episodes of encephalopathy. However, 
later on her condition again deteriorated: upon readmission (4 months after discharge) she 
was lethargic and her speech was slurred. This time slowing of the electroencephalogram 
was obvious: the MDF was 3.8 Hz. Neurological examination revealed a cerebellar 
syndrome: saccadic eye movements, dysdiadochokinesia, impaired coordination and an 
ataxic gait. ACT-scan of the brain did not reveal any abnormalities. Precipitating causes 
of hepatic encephalopathy, such as infections, changes in diet, electrolyte abnormalities, 
obstipation, alcohol intake and use of sedatives or diuretics, could not be identified. The 
serum zinc level and the activity of serum alkaline phosphatase had both dropped once 
again (58 _ug/100ml and 274 U/1, respectively). 
To investigate the possibility of a relation between serum zinc levels and symptoms, she 
was again treated with zinc acetate for a period of 3 weeks. This was followed by a zinc 
depletion regimen under continuous control of her clinical state, quantitative EEG-analysis 
and assessment of serum zinc levels. During the zinc treatment she felt well. Her serum 
zinc level rose to 90 _ug/1 OOml and alkaline phosphatase to 400 U/1. One week after 
stopping zinc administration, zinc loss was induced by L-histidine (8 grams the first day, 
increased incrementally to 32 grams/day on day 7) (5). Urinary zinc levels rose from 1600 
to 8500 _ug/24hrs and serum zinc levels declined (figure 1 ). On day 8 she complained of 
tremor around the mouth and in the hands. On days 9 and 10 anorexia and nausea were 
present and on day 10 she became drowsy and felt depressed. ln the evening she 
wandered around aimlessly, disorientated in time and place, and that night she became 
stuporous. The clinical picture that evolved was recognized by her husband as being similar 
to the episodes at home. She no longer responded to questions and became aggressive 
during (medical) handling. On neurological examination she opened her eyes when spoken 
to loudly, but neither spoke nor followed commands. She actively resisted physical 
examination. Appropriate localizing responses followed the application of a painful stimulus. 
When the limb tendon reflexes were tested both the ipsilateral and contralateral extremities 
responded, in itself not an indication of neurological abnormalities~ On mental status 
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examination an organic brain syndrome was diagnosed with severe clouding of 
consciousness, disorientation and mutism. E!ectroencephalography demonstrated long 
trains of triphasic waves as objective evidence of severe encephalopathy. Serum zinc had 
declined to 46 pg/1 OOml, serum alkaline phosphatase to 235 U~. The arterial ammonia 
levels had been be tow 100 pmol/1 during the study period, except on day 10 when it was 
168 pmot/1. On the morning of the stuporous state it was 79 pmol/1. 
l-histidine was discontinued and zinc acetate given. Lactulose and neomycin dosages 
remained unchanged during the entire study period. A gradual recovery was observed in 
3 days. After 2 days she was cooperative again. Consciousness was still impaired with 
disorientation in time and p!ace, and her memory and cognitive functions were still poor. 
She was very depressed and cried during examination. The following day consciousness 
was normal, her mood had improved markedly and cognitive functions were unimpaired. 
Serum zinc reached normal values within one day of supplementation: 114 pg/dl. Serum 
alkaline phosphatase increased more gradually to 449 U/1 after 10 days. According to her 
husband full recovery was achieved more rapid than at home. 
The patient was discharged from the hospital on zinc acetate therapy, in a dose of 600 
mg/day which was decreased to 200 mg/day in the course of 2.5 months. For a period of 
almost 2 years just one episode of hepatic encephalopathy occurred. At that time the 
patient was obstipated. 
DISCUSSION: 
We have described a patient with chronic liver disease in whom a relation between 
recurrent episodes of encephalopathy and zinc deficiency was demonstrated. At the time 
of admission for recurrent episodes of encephalopathy, her serum zinc level was markedly 
decreased. During an observation period of about 2 months the serum zinc level rose 
spontaneously from 34 to 46 pg/dl but no encephalopathy occurred, despite fluctuating 
hyperammonemia and a 1 00-gram daily protein intake for one week. After zinc 
supplementation for 3 weeks, the serum serum zinc level rose to 91 pg/dl (normal) and she 
felt very well subjectively for about two months. Then mental and neurological 
deterioration developed; the serum zinc level had again dropped to 51 pg/dl. After zinc 
supplementation and complete recovery, histidine-induced zinc loss resulted in an episode 
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of encephalopathy that was identical to earlier episodes. During maintenance therapy with 
zinc acetate, just one period of mental confusion reappeared, this one precipitated by 
obstipation. 
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Figure 1: Clinical course during L-histidine-induced zinc loss and 
supplementation. Upper panel: the symptoms and the course of 
the mean dominant frequency (MDF) of the EEG; middle panel: 
the course of serum zinc levels and the activity of alkaline 
phosphatase in serum; lower panel: the dose of L-histidine during 
the depletion period, the zinc acetate dosage during 
supplementation and protein intake during both periods. (Aik. 
Phosph. alkaline phosphatase, l-Hist l-histidine, MDF mean 
dominant frequency, Zn zinc, ZnAc zinc acetate) 
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The psychiatric and neurological signs and symptoms that were observed have all been 
described as clinical manifestations of hepatic encephalopathy: slowness of speech, 
inappropriate behavior, anger, depression, impaired consciousness, tremor and ataxia (1, 
12). Indeed, the picture of recurrent episodes of encephalopathy in a patient with chronic 
liver disease without neurological or non-hepatic metabolic diseases is consistent with the 
diagnosis of hepatic encephalopathy. 
A syndrome of acute zinc loss has been described in patients with progressive systemic 
sclerosis who have been treated with high doses of l-histidine (5). Neurological symptoms 
consisted oftremor and ataxia; psychiatric symptoms included sleepiness, depressive mood 
and paranoid ideation (5). In our patient the impairment of consciousness seemed to be 
more severe, but the overall clinical picture was almost identicaL Acute zinc deficiency has 
also been described during total parenteral nutrition (6-7, 13-15). Disturbances of mental 
function were less prominent in these studies, although depression and mental confusion 
were reported (6-7). Moreover chronic zinc deficiency in children with acrodermatitis 
enteropathica is often characterized by moody depression (16). The symptomatology of our 
patient, therefore, closely resembles that of hepatic encephalopathy but is also compatible 
with the zinc deficiency syndrome. 
The pathogenesis of hepatic encephalopathy is still poorly understood. The most popular 
theories focus on the role of ammonia, an imbalance between cyclic and branched chain 
amino acids or GABA ( 1 ). All three factors are presumed to influence neurotransmission in 
the central nervous system. Zinc is a major trace element in the human body and is found 
in several enzymes (17). Encephalopathy due to zinc deficiency in patients with an 
underlying liver disease may be attributable to further disturbance of the metabolism of 
specific toxins. Indeed, in healthy volunteers zinc deficiency caused a rise in plasma 
ammonia levels (18) and patients with liver cirrhosis exhibited a stimulated synthesis of 
urea during zinc therapy {8). We observed a high arterial ammonia level just one day before 
our patient became stuporous but did not find a clear relation between zinc and ammonia 
levels in our patient. Furthermore, the plasma ammonia concentrations before and during 
the episode of encephalopathy that followed l-histidine-induced zinc loss were similar to 
or even lower than the values found during the first observation period when 
encephalopathy did not occur. The effect of zinc deficiency also could not be explained by 
a decreased ratio of branched chain to aromatic amino acids (1.05 during encephalopathy 
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and 1 .13 after recovery). Therefore, instead of stimulating the accumulation of toxins, zinc 
deficiency may affect central nervous system functioning by itself and may thus make the 
brain more susceptible to the effects of toxins. Correction of the zinc deficiency may then 
improve the underlying neurone dysfunction and protect against elevated concentrations 
of toxins. As encephalopathy did not occur during the first observation period when zinc 
levels were low but rose slightly, decreasing zinc levels may be especially harmful to the 
brain. 
An effect of zinc on central nervous system functioning is supported by in vitro studies that 
seem to relate zinc to neurotransmission: uptake into synaptosomes (19), depolarization~ 
induced release from brain tissue (20-21) and post~synaptic modulation of excitatory 
neurotransmission (22-23). In addition to neurotransmission, electrophysiologic membrane 
function might also be affected by membrane-associated zinc (24). 
The diagnosis of zinc deficiency is difficult and cannot be based on serum levels only (25). 
In liver disease the diagnosis of zinc deficiency is particularly difficult because of the 
decrease in albumin levels and alterations in the distribution of serum zinc between albumin 
("loosely-bound" zinc) and alpha-2 macroglobulin ("tightly-bound" zinc) (26). Measurement 
of zinc levels in tissues such as hair, leukocytes and erythrocytes has been suggested as 
indicator for the zinc status (27). However, the rapid changes in zinc status as observed 
during our zinc depletion and supplementation periods would not have been reflected 
properly in tissue levels, as tissue turnover is slow (27). On the other hand, rapid increases 
in serum alkaline phosphatase have been reported after treatment of zinc deficiency (28). 
Therefore, we felt justified to use serum zinc levels together with levels of the zinc 
dependent enzyme alkaline phosphatase as a simple method for monitoring zinc status. 
Changing levels of serum zinc in a single patient in whom intercurrent infections and 
fluctuations in albumin levels are absent, seem to indicate changes in the zinc status. The 
close relation between serum zinc levels and the activity of the zinc metalloenzyme alkaline 
phosphatase in serum supports a true state of zinc deficiency. 
The diagnosis of zinc deficiency is further substantiated by analysis of the zinc content in 
the diet and the urine. The zinc content in the diet our patient used at home was rather 
low: 3.8-5.6 mg/day; a higher concentration, 7.0-8.8 mg/day, was found in the hospital 
diet. The difference in zinc content in the 2 diets might explain that the serum zinc level 
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rose from 34 to 46 pg/d! during the first observation period. On readmission, urinary 
excretion of zinc was increased, 2700 pg/day. Urinary zinc concentrations were also 
monitored during histidine-induced zinc loss. The already increased urinary output of 1600 
pg/24hrs just before the use of L-histidine rose to 8500 pg/24hrs at the end of the 
depletion period. Because intestinal absorption of zinc from food is far less than 50% (25), 
urinary zinc loss may account for a rapid induction of zinc deficiency during the 
experimental depletion period. 
Although our observations on the relation between zinc deficiency and manifestations of 
encephalopathy in chronic liver disease suggest a contribution of zinc deficiency to the 
pathogenesis of hepatic encephalopathy, SchOimerich et a! failed to find a correlation 
between serum zinc levels and the presence of hepatic encephalopathy in liver cirrhosis 
(29). However, the estimation of zinc deficiency by serum levels only in a group of patients 
may be much more hazardous than in a single patient. Furthermore, the beneficial effects 
of zinc substitution on mild hepatic encephalopathy, as demonstrated in several studies {8-
11 L further support a pathogenetic role for zinc in hepatic encephalopathy. 
!n conclusion, our observations suggest that overt hepatic encephalopathy can be 
precipitated by zinc deficiency. Further studies are needed to support this finding and to 
evaluate the consequences of zinc substitution for treatment of the various manifestations 
of hepatic encephalopathy. 
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Chapter 10 
DISCUSSION AND CONCLUSIONS 
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The pathogenesis of hepatic encephalopathy is still unknown. Ammonia has been 
suggested as the major etiologic toxin. Medical therapy, consisting of oral protein 
restriction, lactulose or newer disaccharides and/or antibiotics, is aimed at decreasing 
elevated plasma ammonia levels. This strategy, however, is not always successful. 
Especially patients with a severely impaired liver function often respond poorly. 
New theories on the pathogenesis of hepatic encephalopathy were developed, the most 
important being the false neurotransmitter hypothesis based on the imbalance between 
aromatic and branched chain amino acids and the GABA-benzodiazepine receptor 
theory. These theories were rather attracive, because they tried to explain the 
neuropsychological disorder at the neuronal level, i.e. as a disorder of 
neurotransmission. More specific therapies seemed possible. Several clinical trials on 
therapy with branched chain amino acids for hepatic encephalopathy were instituted 
but most of them could not demonstrate a beneficial effect. Direct intervention with L~ 
Dopa or bromocriptine to restore catecholaminergic neurotransmission is possibly 
effective in a few carefully selected patients. The application of the false 
neurotransmitter theory to explain hepatic encephalopathy therefore seems limited (for 
references, see Chapter 1 ). 
The GABA theory for the pathogenesis of hepatic encephalopathy can be discarded in 
view of the controversial findings on the number of GABA receptors, plasma GABA 
concentrations and blood-brain barrier permeability for GABA. Later, the concept of 
endogenous benzodiazepine ligands in hepatic encephalopathy was introduced as a 
result of several observations on the beneficial effect of the benzodiazepine antagonist 
flumazenil in experimental and clinical hepatic encephalopathy. Our negative findings in 
a controlled experimental study and a double-blind controlled clinical trial on flumazenil 
for hepatic encephalopathy do not support this concept. 
Since the start of our double-blind clinical trial on the effect of flumazenil in hepatic 
encephalopathy, evidence has accumulated on the presence of "endogenous" 
benzodiazepine agonists in hepatic encephalopathy (1-3). After the detection of 
benzodiazepine-like compounds by radioreceptor assays (3-4L elevated concentrations 
of well-known benzodiazepines, including diazepam and N-desmethyldiazepam, have 
recently been demonstrated by HPLC and mass spectroscopy in brain extracts from rats 
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with hepatic encephalopathy (5-6). Measurements in cerebrospinal f!uid from humans 
with hepatic encephalopathy also indicated elevated concentrations of N-
desmethyldiazepam {6). Diazepam and its metabolite N-desmethyldiazepam have indeed 
been identified as naturally occurring compounds in animals and humans (7-1 0). 
Therefore, the relevant question now is, what is the significance of naturally occurring 
benzodiazepines in the pathogenesis of hepatic encephalopathy and how can we 
explain our negative findings? 
Table 1: Benzodiazepine activities in human and animal body fluids. 
DZP DM-DZP DZP-E 
(ng/ml) (ng/mll (ng/ml) author, ref nr 
human serum/plasma 
HE 3-12 Olasmaa, 6 
10 mg OZP i.m., peak level ±140 ±40 Kanto, 13 
after 3 hrs ± ±80 
controls < 1.41 Olasmaa, 6 
0.3-3 Wildmann, 7 
human CSF 
HE ± 1.4. ±OS 0.9-14 Olasmaa, 6 
±54 Mullen, 4 
10 mg DZP i.m., peak level ±4 Kanto, 13 
after 3hrs ±2 
controls ± 1.8· ±O.o5· <0.8 Olasmaa, 6 
± 11 Mullen, 4 
rat brain 
HE 11-26 7-9 60-85 Basile, 5 
±21 4 ±9. Olasmaa, 6 
5 mg/kg DZP i.p., after 15min ±860 Mennini, 14 
1.3 mg/kg DZP i.p., after 15 min ±170 ±50 Mennini, 14 
controls 2-4 1-3 ±15 Basile, 5 
± 1. ±5. ±26 Olasmaa, 6 
2-5 2-5 10-20 Wildmann, 8 
DZP diazepam; DM~DZP N-desmethyldiazepam; DZP~E diazepam-equivalents as measured by 
radio-receptor assay; •: diazepam and N-desmethyldiazepam were not measured directly but 
by a radio-receptor assay of a particular peak yielded by HPLC with retention times similar to 
diazepam and N-desmethyldiazepam, respectively. 
Our study has been criticized because we could have excluded potential responders 
from the clinical flumazenil trial by including a benzodiazepine screening assay in the 
selection procedure (4). The precipitation of hepatic encephalopathy by synthetic 
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benzodiazepines is however rather common {11 }. Twelve of the 15 patients excluded 
from our controlled trial because of benzodiazepine use had already been identified by 
history and the study of medical reports; only one patient was excluded on the basis 
of a positive screening test only. Moreover, flumazenil did not affect the grade 2 
encephalopathy when the patient participated in the open part of the study. 
Furthermore, the three responders in the open study had indeed previously been 
treated with benzodiazepines. Our negative findings in the clinical study cannot 
therefore be explained simply by wrong exclusion criteria. Furthermore, a French 
controlled study on flumazenil for hepatic encephalopathy, recently reported in 
preliminary form, also did not demonstrate an effect of flumazenil (12). 
Although benzodiazepine ligands indeed seem to be elevated in plasma, CSF and brain 
tissue from humans and animals with hepatic encephalopathy, hypnotic doses of 
synthetic benzodiazepines induce considerably higher tissue levels {table 1) {13-14). 
Furthermore, the presence of compounds with effects opposite to those of the classic 
benzodiazepines, the so-called inverse agonists, must also be considered. Two of 
these agents, DBI (diazepam-bound inhibitor) and OON (octadecaneuropeptide), have 
been found to be elevated in experimental and human hepatic encephalopathy (15-16). 
The balance between these opposing agents may be more important than the absolute 
cerebral levels of the benzodiazepines alone. On the basis of the results of our study 
with a benzodiazepine antagonist, which directly interfere at the receptor leveL we 
cannot support the concept of endogenous benzodiazepines in hepatic 
encephalopathy. Nevertheless, we studied a small group of patients and larger 
controlled studies are needed for definitive conclusions. 
The "new therapies" proposed for hepatic encephalopathy thus have not changed our 
approach to clinical hepatology. Therapies aimed at reducing the plasma ammonia 
concentration still seem to be the most appropriate but are insufficient for patients 
with chronic portosystemic encephalopathy and encephalopathy due to a markedly 
reduced liver cell function. What makes the treatment of hepatic encephalopathy so 
difficult? Two considerations seem worthwhile: 
1. ammonia is a major toxin but current therapies are unable to achieve a 
sufficient reduction in level, 
2. liver failure induces accompanying complications. 
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Currently, ammonia is again considered to be a major toxin responsible for the 
induction of hepatic encephalopathy (17). Although near normal plasma ammonia 
levels have been reported in severe encephalopathy, a close correlation between 
ammonia and encephalopathy was found in a group of patients studied immediately 
after hospitalization and before the institution of therapy (18). Since ammonia in 
plasma has a half~life expressed in seconds (19), plasma levels may not reflect the 
induced metabolic or physiological alterations with a longer half-life. Indeed, glutamine 
levels in CSF, reflecting ammonia detoxification in the centra! nervous system, exhibit 
a highly significant correlation with the depth of hepatic encephalopathy (20). 
Furthermore, since the detoxification system for ammonia surrounding cerebral 
capillaries is already nearly saturated at physiological ammonia concentrations, just a 
small increase may be sufficient to induce pathological ammonia levels in the central 
nervous system (21-22). The mechanisms of ammonia toxicity in the brain may be 
altered glutamatergic neurotransmission, possibly glutamate neurotoxicity, {23) or 
inhibition of GABA-induced hyperpolarization of the neuronal membrane (24). Once an 
understanding of the underlying mechanism of ammonia toxicity has been achieved, 
new drugs that interfere directly at the neuronal level can be developed. like branched 
chain amino acids, L-Dopa and flumazenil, these drugs will be the ultimate test of the 
relevance of current concepts on the role of ammonia in the pathogenesis of hepatic 
encephalopathy. 
Complications often associated with severe liver disease may also explain problems 
encountered in the treatment of hepatic encephalopathy. Our case-control study was 
performed to identify factors that might contribute to the encephalopathy. The case 
report on zinc deficiency highlighted the importance of screening for modulating 
factors, especia!ty deficiencies. Treatment of zinc deficiency may be especially 
important if the current hypothesis on ammonia-induced glutamate neurotoxicity is 
confirmed, since zinc seems to block the binding of glutamate to its receptor, thereby 
diminishing a possible neurotoxic effect (25). Univariate analysis of the data from our 
case-control study indicated that hepatic encephatopathy was indeed associated with 
the failure of multiple organs. Severe complications such as cerebral hemorrhage (26) 
and hyponatriemia (27) have been reported in the literature but, because of their low 
prevalence, cannot be detected in a case-control study. The specific correlations, 
determined by logistic regression analysis, between encephalopathy and alcohol {or 
138 
granulocytes), ascites and 3,3' ,5-triiodothyronine (T3) have to be further investigated. 
In the event of a role for endotoxins and lymphokines in the precipitation of 
encephalopathy, as suggested by the correlation with alcohol and granulocytes, future 
studies should investigate the effect of antibodies against endotoxins and 
lymphokines. Should the relation between T3 and encephalopathy be causal, 
substitution therapy could be tried. 
On the basis of these considerations with regard to the pathogenesis and treatment of 
hepatic encephalopathy, I propose a strategy for the diagnosis and treatment of 
patients with hepatic encephalopathy in clinical practice: 
1. Non-metabolic neurological disorders have to be excluded by thorough 
neurological examination and further tests, when indicated. 
2. laboratory screening should exclude electrolyte abnormalities, oxygen 
deficiency, acid-base disturbances and disorders of glucose metabolism. 
3. Flumazenil will antagonize benzodiazepines taken n~cently-whether known 
or unknown. 
4. Dietary protein restriction, lactulose and/or neomycin will lower plasma 
ammonia levels and is preferred over newer therapies. 
5. Precipitating causes of hepatic encephalpathy (GASCAPAPI: gastro-
intestinal hemorrhage, azotemia ... , infection) should be treated. 
6. When chronic portosystemic encephalopathy does not react to 
conventional therapy, zinc and bromocriptine may be tried. 
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SUMMARY 
The pathogenesis of hepatic encephalopathy is still unsolved. Therapy, therefore, is 
often insufficient. For the development of effective, new therapies insight into the 
disease-inducing substrates and the mechanisms of its toxic actions in the central 
nervous system ·are required. For both studies on pathogenesis and therapy of hepatic 
encephalopathy, methods for the quantitation of its severity are needed. 
For the measurement of hepatic encephalopathy clinical grading, conventional 
electroencephalography and psychometric tests are mostly used. The former two 
methods are characterized by considerable intra- and interobserver error; the last one 
can only be used in mild encephalopathy. Quantitative EEG analysis has been shown to 
be useful! in longitudinal studies but its value for the classification of the whole 
spectrum of severities of encephalopathy had not been investigated. 
In studies on the pathogenesis of hepatic encephalopathy ammonia was considered as 
a major toxin from the beginning. However, its importance was rejected by many 
hepatologists because the correlation between plasma concentrations and en-
cephalopathy is poor. New theories, especially the false neurotransmitter theory and 
the GABA-benzodiazepine receptor hypothesis, tried to explain cerebral dysfunction 
directly at the neuronal leveL The GABA-benzodiazepine receptor theory as originally 
proposed by Schafer and Jones resulted in the use of flumazenil, a benzodiazepine 
receptor antagonist, in hepatic encephalopathy. Uncontrolled clinical studies seemed to 
indicate remarkable therapeutic activity and therefore supported the presence of 
endogenous benzodiazepines. 
Besides specific toxins little attention has been given to the role of nonspecific 
metabolic factors, often present in liver failure, in the precipitation of encephalopathy in 
liver disease. 
With regard to these considerations the aims of this thesis were: 1. the development of 
an objective method, spectral analysis, for the measurement of hepatic encephalopathy; 
2. to study the effect of flumazenil in hepatic encephalopathy; and 3. to study the role 
of aspecific factors in the induction of hepatic encephalopathy. 
In chapter 2 we evaluated the use of automated EEG analysis to quantitate the depth of 
hepatic encephalopathy objectively in a group of 66 patients with cirrhosis of the liver 
and 51 controls. The mean dominant frequency (MDF) could be used to discriminate 
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between the grades 0-1 (;,6.4 Hz) and 2-4 1<6.4) hepatic encephalopathy. Further 
identification of grade 1 hepatic encephalopathy was possible by the use of the relative 
power of theta activity {=::35%), whereas a relative delta activity ::::70% seemed to 
identify the grades 3 and 4 encephalopathy. A separate study revealed the value of the 
total power of the EEG for the discrimination between the grades 3 and 4 
encephalopathy (;?::250 pV 2 vs <250 pV2 for grade 3 and 4 respectively). Validation of 
the clinical value of objectively grading hepatic encephalopathy was achieved in the 
study described in chapter 3. A highly significant correlation was found between the 
grade of hepatic encephalopathy as measured by spectral analysis of the EEG and 
survival in a group of 60 patients with cirrhosis of the liver and 1 0 patients with acute 
hepatic failure. 
In recent years several modality evoked potentials have been advocated for the 
detection of hepatic encephalopathy. According to chapter 4, no direct evidence to 
support their use over quantitative EEG analysis is yet available. 
The effect of the benzodiazepine antagonist flumazenil on hepatic encephalopathy was 
studied in a rabbit model of acute ischemic liver failure (chapter 5) and a controlled 
double-blind clinical trial {chapter 6). In the animal experiment flumazenil or the placebo 
was administered at two easily recognizable time points in the course of the 
development of hepatic encephalopathy in two groups of 8 rabbits respectively. The 
response of flumazenil did not differ from that of the placebo as measured by clinical 
evaluation of the severity of the encephalopathy, spectral analysis of the EEG and 
survival analysis. 
In the clinical study eighteen patients with hepatic encephalopathy resistant to 
conventional therapy were studied for the effect of f!umazenil and the placebo 
following a cross-over design. Great care was taken not to include patients who had 
used synthetic benzodiazepines by using a plasma screening test. Cross-over analysis 
for the immediate effect of 1.0 mg of fiumazenil could be performed in 16 patients. 
There was a trend toward a decrease in the clinical grade of hepatic encephalopathy 15 
minutes after the injection of flumazenil (p=0.06L but neither conventional EEG-
grading nor spectral analysis changed significantly. In 8 patients cross-over analysis 
could be performed for the effect during a 3-day infusion period 10.25 mg/hr). No 
significant difference between flumazenil and the placebo was found for the clinical 
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grade, the EEG grade and the MDF. In a separate open study 13 patients who were 
excluded from the double~blind study largely because of renal failure or evidence for 
recent benzodiazepine use were studied for the immediate effect of 1 .0 mg of 
flumazenil. The MDF increased significantly in the whole group of patients but clinical 
and/or EEG grades improved only in the patients who had used benzodiazepines. 
Pharmacokinetics of flumazenil as studied in four healthy volunteers and 7 patients 
with acute or chronic liver disease were reported in chapter 7. Elimination half-lives in 
liver disease (2.0-6.6 hrl were 2-6 times the values found for controls (0.85-1.2 hr); 
the plasma clearance rates were decreased 3-5 times (120-320 ml/min and 700-850 
ml!min for patients and controls, respectively). This study was important for the 
evaluation of the duration of the wash-out period in the clinical cross-over study on 
flumazenil. Since the duration of the wash-out period, one day, was about four times 
the longest half-live time, this duration seems appropriate. 
Chapter 8 reports on a study using logistic regression analysis to find which metabolic 
disturbances often found in severe liver disease could be of importance in hepatic 
encephalopathy. Twenty-six cases with encephalopathy and chronic or acute liver 
disease together with 26 cases with liver disease but without encephalopathy were 
selected. Univariate analysis indicated that the group of patients with encephalopathy 
indeed differed from those without encephalopathy with respect to several variables 
representing liver function (liver cerr protein synthesis, detoxification function and liver 
cell damage), infection and endocrinologic function and levels of zinc, glucose and 
vitamins. Furthermore, patients with encephalopathy had more severe ascites and 
consumed more alcohol. Using logistic regression analysis heavy drinking, 
granulocytosis, severe ascites and low serum levels of T3 and zink were selected as 
highly predictive for the presence of hepatic encephalopathy in the patients studied. 
Hypotheses on the relation of these variables to encephalopathy are described. 
The importance of zinc deficiency in clinical hepatic encephalopathy is further 
strenghtened by the case report described in chapter 9. We report on a patient with 
chronic recurrent hepatic encephalopathy resistant to protein restriction and treatment 
with lactulose and neomycin. During substitution therapy for possible zinc deficiency 
the patient improved subjectively but deteriorated after stopping zinc acetate. After a 
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new substitution period, zinc deficiency was artificially induced by l-histidine induced 
urine zinc loss. Severe stupor occurred, the episode being similar to previous ones. 
Chronic substitution therapy followed, without recurrence of severe deterioration of 
consciousness. 
In chapter 10 a discussion on the findings in this thesis is given. The findings do not 
support a beneficial effect of flumazenil on hepatic encephalopathy and therefore 
cannot support the clinical significance of endogenously occurring benzodiazepines in 
the pathogenesis of hepatic encephalopathy. Renewed interest in the role of ammonia 
in the pathogenesis of hepatic encephalopathy is found. Other factors as endotoxins 
and zinc deficiency may contribute to the occurrence of encephalopathy. Direct 
interventions at the neuronal level as described for the GABA-benzodiazepine receptor 
complex have to be developed and tested, especially for ammonia-induced alterations in 
the central nervous sytem. 
In summary, quantitative EEG analysis has been introduced and validated as an 
objective method to measure hepatic encephalopathy. Clinical and experimental studies 
could not support an effect of the benzodiazepine antagonist flumazenil for hepatic 
encephalopathy, and therefore question the role of endogenous benzodiazepines in its 
pathogenesis. New hypotheses were developed following the idea that aspecific factors 
might be important. 
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Omdat de pathogenese van hepatische encephalopathie nag steeds onduidelijk is, heeft 
behandeling vaak onvoldoende effect. Voor de ontwikkeling van nieuwe, effectieve 
therapieen, is inzicht in het ziekte-inducerend substraat met zijn werkingsmechariismen 
in het centrale zenuwstelsel van belang. Voor zowel studies naar pathogenese als naar 
therapie, zijn methoden nodig om de ernst van hepatische encephalopathie te 
quantificeren. 
Voor het meten van hepatische encephalopathie wordt meestal gebruik gemaakt van 
klinische gradering, conventionele electroencephalografie en psychometrische testen. 
De eerste twee methoden worden gekenmerkt door behoorlijke intra- en interobserver 
error; de laatste kan aHeen voor milde encepha!opathie worden gebruikt. In longitudinale 
studies is quantitatieve EEG analyze waardevol gebleken, maar zijn waarde voor de 
classificatie van het hele spectrum van gradaties was nog niet bestudeerd voor de start 
van deze studie. 
In studies naar de pathogenese van hepatische encephalopathie is ammoniak van begin 
af aan beschouwd als een belangrijk toxine. Dit idee werd echter verworpen door 
verscheidene auteurs vanwege een slechte correlatie tussen plasma concentraties en 
encephalopathie. Nieuwe theorieen, speciaal de false neurotransmitter theorie en de 
GABA-benzodiazepine hypothese, probeerden de slechte cerebrale functie direct op 
neuronaa! niveau te verklaren. De GABA-benzodiazepine receptor theorie, zeals 
aanvankelijk gepostuleerd door Schafer en Jones, leidde tot het gebruik van flumazenil, 
een benzodiazepine receptor antagonist, in hepatische encephalopathie. Niet-
gecontroleerde studies Jeken op het bestaan van endogene benzodiazepines te wijzen, 
met belangrijke therapeutische consequenties. 
Behalve voor specifieke toxines is er altijd weinig aandacht geweest voor een raJ van 
aspecifieke metabole verstoringen, die vaak aanwezig zijn bij leverfalen, in het ontstaan 
van encephalopathie bij leverziekte. 
Uitgaande van deze overwegingen was het doel van dit proefschrift: 1. de ontwikkeling 
van een objectieve methode, spectraal analyse, voor het meten van hepatische 
encephalopathie; 2. bestudering van het effect van flumazenil op de hepatische 
encephalopathie; en 3. bestudering van de rol van aspecifieke factoren in het ontstaan 
van hepatische encephalopathie. 
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Hoofdstuk 2 beschrijft een studie naar het objectief meten van hepatische 
encephatopathie gebruik makend van geautomatiseerde EEG analyse in een groep van 
66 patienten met levercirrose en 51 controles. De graden 0-1 en 2-4 hepatische 
encephalopathie konden van elkaar worden onderscheiden met behulp van de mean 
dominant frequency (MDF) (<:6.4 Hz voor graad 0-1 en <6.4 Hz voor graad 2-4 HE). 
Graad 1 hepatische encepha!opatie werd verder gekenmerkt door een verhoogd 
percentage theta activiteit in het power spectrum {=::35 %), terwijl een relatieve delta 
activiteit <::: 70% gevonden werd bij de grad en 3 en 4 encephalopathie. Een a parte 
studie toonde aan, dat een verder onderscheid tussen graad 3 en 4 mogelijk was met 
behulp van de totale power van het EEG: ~250 pV2 voor graad 3 en <250 pV2 voor 
graad 4). Wij onderzochten de klinische waarde van het objectief meten van hepatische 
encepha!opathie in de studie beschreven in hoofdstuk 3. Wij vonden een sterk 
significante correlatie tussen de graad van hepatische encephalopathie, zoals gemeten 
met spectraal analyze, en de overleving in een groep bestaande uit 60 patienten met 
levercirrose en 10 patienten met acuut !everfalen. 
Sinds enkele jaren worden evoked potentials (BAEP's, VEP's en SSEP's) gepropageerd 
om hepatische encephalopathie te detecteren en te quantificeren. Zeals aangegeven in 
hoofdstuk 4, bestaan er vooralsnog geen directe bewijzen voor hun superioriteit boven 
spectraal analyze. 
Het effect op de hepatische encephalopathie van de benzodiazepine-antagonist 
flumazenil werd bestudeerd in een konijnen model voor acuut ischemisch leverfalen 
(hoofdstuk 5) en een gecontroleerde dubbelblinde klinische trial (hoofdstuk 6). In de 
dier-experimentele studie werden flumazenil en placebo toegediend aan twee groepen 
van 8 konijnen; het middel werd op 2 goed herkenbare punten in het beloop van de 
encephalopathie gegeven. Het effect van flumazenil verschilde niet van dat van de 
placebo wat betreft de klinische beoordeling van de ernst van de encephalopathie, 
spectraal analyze van het EEG en de overleving. 
In de klinische studie werden 18 patienten met hepatische encephalopathie die 
onvoldoende reageerde op conventionele therapie behandeld met flumazenil en placebo 
volgens een cross-over studie-design. Om patienten met recent gebruik van 
synthetische benzodiazepinen uit sluiten van de studie, werd een analyze van het 
plasma hierop verricht. Cross~over analyze voor de beoordeling van het directe effect, 
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15 minuten na toediening van 1,0 mg flumazenil, was mogelijk voor 16 patienten. Deze 
toonde een trend van verbetering na flumazenil wat betreft de klinische graad van 
encephalopathie (p=0.06), maar conventionele EEG gradering en spectraal analyze 
toonden geen significante veranderingen. Voor 8 patienten was cross-over analyze 
mogelijk wat betreft het effect van flumazenil tijdens een 3 dagen durende infusie van 
0,25 mg/uur. Wij vonden geen significante verschillen tussen flumazenil en placebo wat 
betreft klinische graad, EEG graad en de MDF. Dertien andere patienten die waren 
uitgesloten van de dubbel-blinde studie, voornamelijk wegens nierfalen en recent 
benzodiazepine gebruik, werden opgenomen in een open studie naar het directe effect 
van 1,0 mg flumazenii. De MDF Steeg significant voor de gehele groep patienten, maar 
de klinische en EEG graad van encephalopathie verbeterden aileen voor de patienten die 
recent benzodiazepinen gebruikt hadden. 
De farmacokinetiek van flumazenil, zeals bestudeerd in 4 gezonde vrijwilligers en 7 
patienten met acute en chronische leverziekte is beschreven in hoofdstuk 7. De 
eliminatie halfwaarde tijd was 2-6 keer verlengd in de leverpatienten (2,0-6,6 uur) ten 
opzichte van de contro!es (0,85-1 ,2 uur); de plasma klaring was 3-5 keer verlaagd 
(120-320 ml/min en 700-850 ml/min voor patienten, respectievelijk controles). Oeze 
studie was belangrijk voor de beoordeling van de wash-out periode in de klinische 
flumazenil cross-over studie. Omdat de duur van de wash-out peri ode, 1 dag, ongeveer 
vier maal zo lang was als de grootste halfwaarde tijd, lijkt deze duur adequaat. 
In hoofdstuk 8 wordt een onderzoek beschreven waarin logistische regressie analyze 
toegepast werd om frequent voorkomende, metabole ontregelingen bij patienten met 
een ernstige leverziekte te correleren aan de aanwezigheid van encephalopathie. 
Zesentwintig patienten met encephalopathie en chronische of acute leverziekte en 26 
patienten met leverziekte zonder encephalopathie werden geselecteerd. Univariate 
analyze toonde aan, dat de 2 groepen patienten van elkaar verschilden met betrekking 
tot velerlei variabelen betreffende leverfunctie (eiwitsynthese door de lever, ontgiftiging 
en levercelverval), infectie en endocriene functie, en plasma/serum concentraties van 
zink, glucose en vitamines. Patienten met encephalopathie hadden tevens ascites in 
ernstiger mate en zij gebruikten meer alcohol. Met behulp van logistische regressie 
analyse werden de volgende factoren geselecteerd als meest voorspellend voor de 
aanwezigheid van encephalopathie: het gebruik van vee! alcohol, granulocytose, 
149 
ernstige ascites en lage serum concentraties van zink en T3. In het hoofdstuk worden 
hypothesen genoemd met betrekking tot de relatie tussen deze factoren en 
encephalopathie. 
Het belang van zink deficientie bij de patient met hepatische encephalopathie wordt 
verder gesteund door de case report in hoofdstuk 9. Wij beschrijven een patient met 
chronisch recidiverende hepatische encephalopathie ondanks eiwitbeperking en 
behandeling met lactulose en neomycine. Tijdens zinksubstitutie op verdenking van 
zinkdeficientie trad een subjectieve verbetering op, maar de patient verslechterde 
opnieuw na staken hiervan. Na een nieuwe substitutie periode werd zinkdeficientie 
gecontroleerd geinduceerd met behulp van l-histidine, wat !eidde tot zinkverlies met de 
urine. Er ontstond een stupor die vergelijkbaar was met eerder doorgemaakte episoden 
van encephalopathie. Tijdens onderhoudsbehandeling met zinksubstitutie deden zich 
soortgelijke episoden niet meer voor. 
Hoofdstuk 10 bespreekt de conclusies van dit proefschrift. De resultaten geven geen 
steun voor een therapeutisch effect van flumazenil op hepatische encephalopathie en 
daarom oak niet voor de klinische relevantie van endogene benzodiazepinen in de 
pathogenese van hepatische encephalopathie. Opnieuw is interesse ontstaan naar de rol 
van ammoniak in de pathogenese. Andere factoren zeals endotoxinen en zinkdeficientie 
kunnen mogelijk een rot spelen in het ontstaan van encephalopathie. Directe 
interventies op neuronaal niveau, zeals beschreven voor het GABA-benzodiazepine 
receptor complex, moeten ontwikkeld en getest worden, speciaa! met betrekking tot 
ammoniak-geinduceerde veranderingen in het centrale zenuwstelsel. 
Samenvattend is quantitatieve EEG analyse geintroduceerd en gevalideerd als objectieve 
meetmethode bij hepatische encephalopathie. Klinische en dierexperimentele studies 
gaven geen steun voor een effect van de benzodiazepine-antagonist flumazenil op 
hepatische encephalopathie, en daarom oak niet voor een rol van endogene 
benzodiazepinen in de pathogenese. Naar aanleiding van de hypothese dat aspecifieke 
factoren van belang zouden zijn, werden nieuwe ideeen ontwikkeld. 
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